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 Many gram-negative bacterial pathogens employ type III secretion systems 
(TTSS) to transport effector proteins into eukaryotic host cell membranes and 
cytoplasms to subvert normal cellular functions.  TTSSs contain a basal body which 
spans the inner and outer bacterial membranes and a needle which extends the into 
extracellular space.  With the increasing prevalence of drug resistant bacterial strains, 
vaccines represent one of the most promising strategies to combat these diseases.  
Proteins located at the extracellular needle tip of TTSSs appear to be excellent 
candidates for a sub-unit vaccine approach.  These so called tip proteins are surface 
exposed and regulate the secretion of other effector proteins.  This work presents pre-
formulation, formulation and animal studies focused on creating a single multivalent 
sub-unit vaccine for five gram-negative pathogenic systems.  In addition, a putative 
tip protein from Chlamydiae is compared to the other tip proteins using biophysical 
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1.1  Overview 
 
Since Edward Jenner’s work Variolae Vaccinae in 1798, vaccines have held 
the promise of eradicating many serious diseases from the world.  Naturally occurring 
infections from smallpox, the focus of Jenner’s initial experiment, have been 
relegated to history and polio is on the verge of being so.1  Despite such success, 
progress in vaccination has historically been viewed with skepticism and fear in some 
segments of society.  Shortly after Jenner’s publication, British satirist James Gillray 
distributed cartoons of vaccinated subjects growing bovine heads on their 
appendages.  More recently, assertions that MMR (measles, mumps, and rubella) and 
thimerosal containing vaccines caused autism in children set off a firestorm of anti-
vaccination campaigns despite a lack of evidence.2  Regardless of its detractors, 
vaccination has had a greater impact on mortality reduction than any other factor 
except for water sanitation and treatment in the last 200 years.3  Diseases such as 
smallpox, diphtheria, tetanus, yellow fever, poliomyelitis, measles, mumps and 
rubella have been completely eradicated from many parts of the world.   
While there has been much success, many serious infectious diseases remain 
without effective vaccines.  Pathogenic gram-negative bacteria have been responsible 
for some of the most serious epidemics in the history of mankind including the 
bubonic plague.  Salmonella outbreaks still occur in the United States with 
regularity.4,5  Until the discovery of penicillin by Alexander Fleming and the 
subsequent proliferation of antibiotics, little could be done to effectively treat 
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patients.  Almost immediately, however, after the introduction of antibiotics, drug 
resistant bacterial strains emerged.6-8  The need for protective vaccines has therefore 
become paramount.   
Many of these pathogens employ type III secretion systems (TTSS) to 
facilitate interactions with host organisms.9-11  These systems possess proteins which 
are ideal candidates for sub-unit vaccines based on their location and function.  
Detailed in the following pages are pre-formulation and formulation experiments for 
five of these TTSS proteins.  Additional experiments for a putative sixth candidate 
receive attention in the fifth chapter.  Despite extensive research on two of these 
proteins (LcrV and PcrV), this work represents the first publication describing 
formulation of these antigens.  In addition, results here establish the antigenicity of 
proteins IpaD and SipD when adsorbed to an aluminum salt adjuvant.  The overall 
goal of this work is explore the possibility of creating one protective, multivalent sub-
unit vaccine against several gram-negative pathogens with sufficient stability for 
distribution in the developing world.   
 
1.2   Pathogens 
 
Six proteins are analyzed in this work, each of which belongs to a different 
gram-negative bacterial system.  The first pathogen that will be discussed is Shigella 
flexneri which is responsible for an estimated one million deaths a year.12  S. flexneri 
is a rod shaped bacteria which causes bacillary dysentery (commonly referred to as 
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Shigellosis) by invading the colonic epithelium.  Transmission occurs via the fecal-
oral route typically through contaminated food or water.  The agent requires as few as 
100 bacteria to initiate infection.13,14  Unlike many of the pathogens listed here, only 
other primates exhibit a disease state upon S. flexneri exposure.15 
 The genus Yersinia spp. contains rod shaped species responsible for a diverse 
list of diseases.  The infamous bubonic plague is attributed to Yersinia pestis.  Y. 
pestis primarily infects rodents and the pathogen is transmitted to humans through 
flea vectors.16  The pathogen has a tropism for lymph tissue where it evades the 
immune system through a number of methods including inducing apoptosis of 
macrophages.17,18  Draining lymph nodes swell during infection, becoming 
hemorrhagic causing the black buboes associated with the disease.  As the disease 
progresses in human hosts, it induces bacterial pneumonia creating a second route of 
infection.16  Aerosol droplets from patients in this late stage are highly contagious and 
without treatment individuals infected by this route have a nearly 100% mortality 
rate.   
 Y. enterocolitia induces the other significant infection caused by this genus in 
humans.  Like Y. pestis, humans are not the natural host but are typically infected by 
ingesting dairy products or water contaminated with carrier animal feces.19-21  Y. 
enterocolitia invades the Peyer’s patch causing necrosis which leads to diarrhea, 
splenic and hepatic abscesses and lymphadenopathy.19,22  Loci for infection are 
northern Europe and Japan.   
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 The Salmonella genus encompasses an amazingly diverse set of organisms 
with a complicated and perpetually evolving taxonomy.  In general, the genus is 
characterized by flagellated, rod shaped, aerobic organisms which are nearly all 
pathogenic.  S. enterica alone includes up to 2000 recognized serovars including 
Typhi, Paratyphi and Typhimurium.  Typhoidal serovars are responsible for an 
estimated 20 million cases yearly (mostly in the developing world) with patient 
relapses common.23,24  Diagnosis is at times difficult since infection causes a broad 
range of symptoms.  Severe cases, however, generally present with high fever, 
myalgia, abdominal pain and malaise.25  Transmission typically occurs through 
contaminated water although a human carrier state also plays a role in endemic 
areas.26   
 The S. enterica serovar Typhimurium is also typically spread through unclean 
water or food and induces gastroenteritis.  Recently, there have been several 
outbreaks of this pathogen in the U.S. and it continues to be a health threat throughout 
the world.4,5  Like serovar Typhi, Typhimurium invade the intestinal mucosa, 
although, the pathogenesis of the serovar diverge after that initial stage.  Typhi 
incubates in the reticuloendothelial system eventually precipitating systemic infection 
while Typhimurium remains near the intestinal mucosa causing acute inflammation 
ultimately leading to diarrhea.27-29 
 Burkholderia pseudomallei, the causative agent of melioidosis, is a disease 
endemic to Southeast Asia.  This gram-negative, aerobic, rod shaped bacillus is found 
in the soil throughout that region with northern Thailand considered a major 
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focus.30,31  B. pseudomallei typically infects humans through inhalation or cutaneous 
inoculation with cases occurring most often in the rainy season.31  The pathogen is 
capable of invading many cell types including epithelial cells and spreads between 
cells through a number of routes including inducing cell fusion.32  Compared to other 
bacteria discussed here, less in known about the virulence factors and life cycle of 
Burkholderia pathogens.   
 Pseudomonas aeruginosa causes many of the nosocomial infections 
encountered in hospitals today.33  P. aeruginosa survives in most moist environments 
encountered in daily life.  Populations considered most at risk include cystic fibrosis, 
AIDS and other severely immunocompromised patients.34,35  Like the bacteria above, 
this pathogen is aerobic and rod shaped.  As an opportunistic pathogen, P. aeruginosa 
infects both animals and some plants with infection in humans leading to sepsis in 
severe cases.  Hospital acquired cases are sometimes antibiotic-resistant making some 
infections chronic.34,36 
 The Chlamydiae phylum contains obligate intracellular pathogens which 
cause numerous sexually transmitted diseases and ocular trachoma.  Chlamydia 
trachomatis has received more study than other related species due to its prevalence 
(~92 million cases yearly).37  Many of the pathogenic details discussed here for C. 
trachomatis apply to other species as well.  The pathogen invades epithelial host cells 
as a metabolically inactive elementary body (EB) which forms an inclusion in the 
eukaryotic cytosol.38-40  Within the inclusion, EB’s transform into metabolically 
active reticulate bodies capable of binary fusion.38  After proliferation within the 
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inclusion, the EBs differentiate back to RBs and are ultimately exocytosed to infect 
neighboring eukaryotic cells.41 
 
1.3 Vaccines and other therapeutic approaches 
 
While antibiotics have been invaluable in combating the infections of many of 
these pathogens, drug resistance (more alarmingly multi-drug resistance) has 
increased dramatically in the last 25 years.7  In the case of Shigella and Salmonella, 
multiple drug resistance appears increasingly commonplace in the developing world 
and is beginning to emerge in more developed nations.42-47  Antibiotic resistance 
appears less advanced in Yersinia spp. with only sporadic cases reported.48,49  Both B. 
pseudomallei and P. aeruginosa exhibit some intrinsic multi-drug resistance due to an 
homologous drug efflux pump.50-52  Interestingly, while the two bacterial systems 
have similar efflux machinery, the drugs selected for export are different.  As noted 
above, in addition to the inherent resistance, hospitals are reporting strains of P. 
aeruginosa seemingly unaffected even by later generation antibiotics.34,36  The first 
clinical report of multi-drug resistance to C. trachomatis did not appear until 2000,53 
however, given the high percentage of asymptomatic cases, the number of patients 
presenting with resistant strains is expected to explode in the coming years.53-55   
Given the prevalence of drug resistant organisms, vaccines represent an 
attractive, prophylactic alternative.  Vaccine strategies for most of these pathogens 
have focused on attenuated or killed whole cells with less consideration given to sub-
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unit strategies.  Phase I or even more advanced trials have been conducted on 
attenuated constructs for Shigella flexneri, Salmonella enterica serovar Typhi, 
Burkholderia pseudomallei, Yesinia pestis and Pseudomonas aeruginosa.15,16,31,33,56-64  
The trials show promise for this approach, but safety concerns along with scale-up 
challenges have so far prevented their commercialization.15,65-67  Interestingly, 
Salmonella enterica serovar Typhimurium and Yersinia enterocolitica attenuated 
strains have been employed primarily as vehicles for other vaccine candidates 
including cancer prophylaxis.68-72  
Initial attempts at creating vaccines for most of these pathogens involved 
killed whole cells.  These approaches were less successful than hoped.  Near the end 
of the second world war for instance, a vaccine for Yersinia pestis was created and 
manufactured by treating a strain with formaldehyde.73  Unfortunately, the vaccine 
requires multiple subcutaneous injections over the course of the first year and annual 
boosts thereafter.74  Common side-effects of the vaccine include malaise, headaches 
and elevated temperatures.75,76  For similar reasons, many killed vaccines to these 
gram-negative bacteria have been abandoned.77,78 
Many of the initial sub-unit vaccines relied on lipopolysaccharides as the 
primary antigen with varying degrees of success.15,33,79-81  One of the most promising 
studies with this approach was conducted in the late 1990’s in Israel using an O-
specific polysaccharide conjugate.82,83  The results indicated that in 74 % of the 
volunteers protection was conferred (or at least significant mediation of symptoms) 
and titers to the conjugate were still detectable two years after the administration 
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cycle.  This sub-unit vaccine also exhibited an excellent safety record with no serious 
side effects indicated.  Despite these encouraging signs, the high production cost of 
the candidate is considered the major challenge to further scale up.84  Other sub-unit 
antigens currently being explored include pili, flagella, bacterial nucleic acids and a 
number of bacterial extracellular and outer membrane proteins.15,16,31,33,61,62,64,85,86 
 
1.4 The Type III Secretion System 
 
 One relatively new source of potential antigens for sub-unit vaccines is the 
type III secretion system (TTSS).  Over 25 bacterial species employ TTSS machinery 
to facilitate interactions with other organisms either as symbionts or pathogens.9  
These systems function as injectisomes, translocating effector proteins from the 
bacterial cytosol to the eukaryotic host cell membrane or into its cytoplasm.  The 
genetic information for TTSSs is typically located on separate virulence plasmids or 
in clusters near one locus known as pathogenicity islands.11  Furthermore, pathogenic 
bacterial strains are often only distinguishable from closely related species by these 
genetic islands while distantly related pathogens often contain closely related 
virulence genes.11  These two observations suggest that the horizontal transfers, in 
which many of these organisms acquired virulence factors, occurred after 
evolutionary branching.  Chlamydiae represent an unusual case since virulence genes 
for these pathogens are located at multiple loci throughout the genome.87    
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While the TTSSs are related genetically, the effectors translocated by 
respective organisms possess a wide array of diverse functions.  It appears that 
subsequent to horizontal gene transfer that the gram-negative pathogens adapted a 
secretion apparatus to meet their needs.  Based on genetic and phylogenic studies, 
TTSSs are divided into seven sub-families.9,88  The Clamydia phylum has its own 
sub-family as does the Rhizobiales order.  The two groupings which receive most of 
the focus in the work presented here are the Ysc and SPI-1 sub-families whose 
archetypes are the Yersinia spp. and Shigella flexneri injectisomes respectively.  
Some pathogens, such as Salmonella spp., encode two separate injectisomes, each 
having a different role.  These differences in TTSS groups are important to remember 
for the following chapters.  The proteins explored here are shown to divide into 
analogous sub-famlies based on response to pH and temperature. 
 TTSSs are composed of more than 20 distinct proteins which form a basal 
body which extends from the bacterial cytosol through both the inner and outer 
membrane.  A needle, comprised of monomers which polymerize, extends from this 
structure into the extracellular space.  It is through a pore in the needle which effector 
proteins must ultimately pass.  One of the most highly conserved injectisome proteins 
is an ATPase associated with the inner membrane.  In Pseudomonas syringae this 
proteins forms a hexamer which in turn becomes a dodecamer.89  Upon 
oligomerization this complex becomes active.  The purpose of this complex is two-
fold.  First, the ATPase energizes transport of effector proteins into the needle and 
second, the complex is believed to detach the effector substrates from their 
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chaperones.90  The stoichiometry and location of many of the other basal components 
has not yet been been elucidated and will not be discussed here.     
 Using single particle analysis cryo-electron microscopy, Blocker, et al. were 
able to determine the structure of the needle complex of Shigella flexneri at high 
resolution.91  This work revealed the dimensions of the inner channel which extends 
from the cytosol to the extracellular needle tip.  The diameter of this channel was 
shown to be 2-3 nm indicating that effector proteins must unfold (at least their tertiary 
structural elements) to pass through.  Notably, an additional role for the ATPase 
complex may be to unfold the effector proteins before passing them into the needle 
complex. 
 The needle is a straight tube approximately 60 nm in length composed of 100-
150 identical molecules.92-94  Needle monomers polymerize in a helical pattern 
forming part of the channel discussed above with ~5.6 monomers per turn.94  One of 
the major areas of current investigation is how needle length is determined.  At least 
three theories have been proposed to account for the change in substrate passage 
(from needle monomer to other effectors) which would determine needle length.9,10  
The cup model asserts that subunits accumulate in a cavity just below the apparatus 
and the volume of monomers in that cavity determines the length.  Flagellar system 
are proposed to function by a similar mechanism and genetic and phylogenic 
information suggest that TTSSs and flagella have a common ancestor.88,95  Indeed, the 
physical polymerization mechanism of TTSS needle monomers is analogous to 
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extracellular flagellum growth.94,96   While these similarities make this an attractive 
model, no requisite C ring (the “cup” in this model) has been discovered.   
 The second theory proposes that a “molecular ruler” controls the length of the 
needle.  In this case, an extended polypeptide (YscP in Yersinia spp.) is anchored to 
the tip of the growing needle and the base of the needle complex.97  Once this protein 
is fully extended it would, through some unknown mechanism, signal a switch in 
substrate specificity in the secretion apparatus.  One major challenge of this model is 
the location of the “ruler”.  If this protein were located inside the channel as seems 
most likely, it would block the channel for the passage of needle monomer.  Finally, 
the third model proposes that completion of the inner rod switches the substrate 
specificity.98  The inner rod creates the channel within the basal body and connects to 
the needle.  This model proposes that the two different channel components are 
assembled simultaneously and that once the rod is completed, the needle stops 
growing as well.  Recent experiments suggest however, that this model (developed in 
Salmonella spp.) may not work in Yersinia spp. where rod formation is not concurrent 
to needle polymerization.9 
 After the needle has been assembled, a protein passes through the channel and 
localizes on the needle tip.99,100  The so called tip proteins possess a central coiled coil 
flanked by N and C-terminal domains.101-103  The N-terminal domain of these proteins 
appears to serve as a molecular chaperone, preventing premature oligomerization.101  
Many of the tip proteins that have been studied are between 33 and 38 kDa in size 
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and have pI’s between 4.8 and 5.5.  These tip proteins regulate the secretion of other 
effectors passing through the needle complex.   
Studies of Invasion plasmid antigen D (IpaD), the tip protein in Shigella 
flexneri, were the first to elucidate much of what is currently understood about the 
function of these proteins.  Transmission electron micrograph (TEM) assays, with 
immunogold-labeled IpaD, demonstrated that IpaD is localized at the needle tip.99  A 
close homolog, BipD of Burkholderia pseudomallei, also localizes to the needle tip in 
the Shigella system.  In silico modeling of other tip proteins suggest that both the N-
terminal domain and the C-terminal end of the coiled coil are required for docking to 
the needle although this has not yet been demonstrated in vitro.104   It has been shown, 
however, that IpaD controls the secretion of the ensuing proteins and that IpaD may 
form a pentamer (or possibly heteropentamer) on the needle tip.99,101,105,106  The 
protein which may be involved in the oligomer besides IpaD is IpaB.  IpaB and IpaC 
form the translocon pore in the eukaryotic host cell permitting entry of further 
substrates to subvert normal cell function.  In aqueous conditions only IpaD is 
detectable on the needle tip.  When bile salts such as deoxycholate (DOC) are added, 
however, IpaB translocates to the needle tip.107  Since Shigella flexneri invades the 
intestinal mucosa, the presence of bile salts is potentially physiologically relevant.  
Additional work has demonstrated that IpaD binds DOC.108  These results suggest 
that bile salts trigger the needle complex to prepare IpaB for insertion into the 
eukaryotic membrane.  Thus, IpaD has a possible role in facilitating the insertion of 
IpaB into the membrane.   
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While interactions with small molecules have not been demonstrated for other 
tip proteins, characteristics such as pentamer formation have been shown.  Employing 
molecular modeling, Deane et al. first predicted that the Yersinia spp. tip protein, 
Low Calcium Reponse protein V (LcrV),  would form such a structure at the needle 
tip.104  Recently, the oligomerization behavior of LcrV has been confirmed in vitro, 
although, the exact size of the higher order species was not determined.109  This 
oligomerization tendency will be important in chapter 5 when we study a newly 
discovered putative tip protein for Clamydiae.   
 
1.5   TTSS Tip Proteins as Potential Vaccine Antigens 
 
 Due to their location at the tip of the needle where they are solvent exposed, 
tip proteins make promising candidates for sub-unit vaccine antigens.  Furthermore, 
studies with IpaD, LcrV and PcrV (of Pseudomonas aeruginosa) have shown that, in 
vitro, antibodies against them block host cell invasion.99,110,111  This makes sense 
since antibodies might prevent interactions with small molecules or with other 
external stimuli.  The antibodies may also physically impede the passage of other 
effector proteins and roles that tip proteins may play in inserting pore forming 
effectors into the host cell membrane.    
 While many of the tip proteins discussed here have received attention as 
possible antigens for sub-unit vaccines, the most interest has been in LcrV and PcrV.  
These antigens were considered promising even before their function was known.  
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Antibodies to LcrV (then known as the V-antigen) were purified in small quantities in 
1963 and shown to passively protect against plague in mice.112  Immunization studies 
with attenuated Yersinia vaccines in 1983 suggested that LcrV had a significant role 
in protection in humans and was cross protective within the genus.113  Though not 
discovered as early, anti-PcrV production has been shown to correlate with higher 
survival rates in humans.114  In addition, passive immunization with polyclonal 
antibodies to PcrV was protective in murine models as well.115,116  These results 
prompted researchers to begin vaccine tests with recombinant LcrV when it became 
available. 
In the mid-1990’s, immunization with recombinant LcrV was shown to 
protect against the plague.117  Initial efforts for LcrV focused on a combination 
vaccine that included capsular antigen F1.  A single dose of F1 purified from cell 
culture supernatant with recombinant LcrV adsorbed to aluminum salt adjuvant 
protected mice from a lethal dose of the plague organism.111  Fusion proteins of LcrV 
and F1 have also been created and tested with some success.118  Strains of acapsular 
Yersinia spp., however, are not uncommon.  Therefore, LcrV is the key antigen in any 
such combination.  Other vaccine strategies with LcrV include microsphere 
encapsulation with poly-L-lactide (PLLA) which was then homogenized by 
sonication with polyvinyl alcohol to form a double emulsion.119    Included in the 
polymeric sphere was another capsular protein known as Caf1.  This microsphere 
only required a single dose delivered intra-nasally to produce protection.  Both helper 
T cell 1 and 2 (Th1 and Th2) cytokines were detected in response to immunization 
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indicating that both cellular and humoral immune responses were activated.  Finally, 
DNA based vaccines which encode LcrV have been tested.  The most successful of 
these nucleic acid based approaches include additional sequences known to elicit 
strong immune response.120  PcrV has also been successfully administered as a sub-
unit vaccine in BALB/c mice with challenge studies indicating protection.115  Many 
of the same approaches which have shown promise with LcrV also work for 
PcrV.33,121   
 While LcrV is considered a promising antigen, the protein has been reported 
to suppress gamma interferon (IFN-γ) and tumor necrosis factor alpha (TNF-α).  
These cytokines function as important proinflammatory signals in the immune 
response.122  It is currently thought that this is accomplished by induction of 
interleukin 10 (IL-10) which is achieved by signaling from a TLR2/TLR6/CD14 
complex.123,124  Since the full length LcrV sub-unit vaccines discussed above protect 
against lethal challenges given days after inoculation, it is not clear what implications 
this has for immunization purposes.  The primary concern raised by some researchers 
is that immediately following vaccination a patient might be immunosuppressed and 
more susceptible to other infections. This has not, however, been established.  In light 
of this concern, two regions of LcrV primarily responsible for protection have been 
identified.  These regions are from amino acids 2 to 235 and from 235 to 275 in the 
primary sequences.125,126  In addition, deletion of residues from 271 to 300 was 
reported to mitigate anti-inflammatory activity while preserving protective effects.127  
This deletion removes an α-helical portion of the protein involved in the coiled coil.  
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While the mutant retained solubility characteristics similar to the wild type, it is not 
clear what effect this deletion had on overall protein secondary and tertiary structure 
and their stability. 
 IpaD has received less attention as a sub-unit vaccine but shows promise.  In 
most monkeys in one study, anti-IpaD IgG and IgA immune responses increase 
dramatically after Shigella infection.128  A few of the monkeys in that experiment 
were infected and fully recovered without producing detectable concentrations of 
IpaD antibodies indicating that while immune response to IpaD may be protective, it 
is not the only antigen which provides protection.    In a study of humans in an area of 
Peru where Shigella inefections are endemic, it was shown that Ipa (IpaB and C 
included) antibodies in the mucosa limited the severity and spread of shigellosis.79  
Epitope mapping of IpaD revealed that most of the surface exposed epitopes were 
located in the N-terminal domain between residues 14 and 77.129  In contrast, residues 
in the carboxyl-terminal region were primarily buried and would therefore be 
inaccessible to antibodies.  It is likely that these epitopes are exposed during 
processing in antigen-presenting cells and are subsequently presented to the adaptive 
immune system.  Interestingly, most of the sequence homology occurs between IpaD, 
BipD and SipD (Salmonella spp.) in the C-terminal region.  Epitopes recognized by 
antibodies are probably therefore heterogeneous while sequences presented by 
antigen presenting cells may have high sequence homology.  It is not yet clear if such 
a pattern would result in immunological cross-reactivity.   
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 BipD is the last of the tip proteins discussed here to have undergone 
significant sub-unit vaccine testing.  Immunization using BipD with Freund’s 
complete adjuvant (FCA) or Brucella abortus O-polysaccharide as an adjuvant failed 
to prolong survival of mice given a lethal dose of Burkholderia pseudomallei.130  
FCA is an oil in water emulsion which contains inactivated mycobacteria.  Both of 
the adjuvants boosted the cellular immune response while FCA also elicited a robust 
humoral response in this study.  B. pseudomallei functions primarily as an 
intracellular pathogen so antibody production might not be expected to protect. Why 
protection was not affected by the Th1 immune pathway is unknown.  The authors 
noted that BipD was not detected during infection suggesting that BipD expression 
may be significantly lower upon infection compared to other pathogens’ TTSS tip 
proteins.  Additionally, human antibody responses to BipD upon B. pseudomallei 
infection are higher than that detected in murine models which could be due to 
differences in the nature of the host immune response.   
 
1.6  Creating Sub-unit vaccines 
 
 While several of the antigens in this study have been shown to be highly 
immunogenic and protective, little has been done to systematically formulate these 
antigens as vaccine products.  Vaccines for Shigella flexneri, Salmonella spp., 
Burholderia pseudomallei and Yersinia pestis are particularly important in the 
developing world where these diseases are endemic.12,23,30,50,64  As antibiotic 
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resistance increases, treatment requiring second line antibiotics may become too 
expensive for regions most in need.  Additionally, effective vaccines would eliminate 
the danger of bacteria resistant to all antibiotics.  Creating viable vaccines for the 
developing world requires highly stable formulations.  In developed countries, a 
labile product might prove commercially viable by employing freezing or 
refrigeration.  The lack of a reliable cold chain, however, in parts of the developing 
world requires formulations with sufficient stability for distribution and 
administration in harsher conditions.131  As such, a systematic, scientifically sound 
approach must be undertaken to ensure that a vaccine is as stable and viable as 
possible.  One of the goals of the formulation process discussed in this work is to 
formulate a vaccine containing IpaD, BipD, SipD, LcrV and PcrV in various 
combinations for specific locations.  This plan for a multivalent vaccine presents 
further challenges since a successful formulation must increase stability for all five 
proteins. 
 To achieve formulations with maximal stability, we employ various 
spectroscopic techniques to measure the conformational stability of the tip proteins 
with respect to pH and temperature.  Far-UV circular dichroism, fourier transform 
infrared spectroscopy, UV absorbance spectroscopy, ANS extrinsic fluorescence, 
turbidity and right angle static light scattering are all employed to monitor secondary, 
tertiary and quaternary structure as well as aggregation behavior.  This biophysical 
characterization lays the groundwork for selecting formulation conditions, excipient 
screening and optimization parameters and long term stability studies.  Data produced 
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later in the formulation process can usually be understood in the context of the initial 
characterization.  Thus, biophysical characterization provides a wealth of background 
information concerning protein conformational stability which enables us to logically 
arrive at an optimized formulation and interpret subsequent findings.   
 In addition to its utility in formulation, biophysical characterization and the 
empirical phase diagrams (EPD) produced as a result afford insights into the 
biological structure/function of proteins as well.  EPDs provide an intuitive way 
analyze data combined from disparate techniques.  The theory and mathematics 
underlying EPDs are covered in detail by Kueltzo et al. elsewhere.132  Briefly, 
however, at each pH and temperature, data are combined from multiple techniques 
and used to create multi-dimensional vectors.  Vectors for each pH\temperature 
conditions are assembled to produce a density matrix.  Eigenvectors and eigenvalues 
are calculated from this matrix.  The three largest eigenvalues are selected to create 
eigenvectors which expand a truncated form of the data set to three dimensions.  
These newly constructed vectors are finally plotted as a combination of three colors 
(red, green and blue).  Differences in color between pH/temperature blocks in an EPD 
represent changes in the protein structural and association state.  Such alterations in 
conformation and aggregation represent apparent “phases” of protein stability. These 
phases are not, however, thermodynamic in nature since no equilibria are implied 
between the “states”.  Proteins with little primary sequence homology but similar 
structure/function relationships generally produce EPD’s which have comparable 
phases.133  In the following chapters, the EPD’s ability to indicate structure/function 
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relationships is used to reveal tip protein sub-families and to indicate the potential 
function of a newly discovered protein from the Chlamydiae TTSS.   
 Stabilizing proteins in solution is often accomplished by adding various 
chemical agents, termed excipients.  These excipients stabilize through a number of 
mechanisms including preferential hydration, minimization of protein-protein 
interactions, exclusion of proteins from destabilizing interfaces and inhibition of 
chemical degradation.134  To achieve significant shelf life, particularly in harsher 
temperature environments, excipients are usually necessary.  Preferential hydration 
occurs when the excipients are excluded from the protein’s immediate environment 
which favors a smaller surface area and increases the free energy of unfolding.135-137  
This mechanism of protein stabilization proved to be the most important in the work 
described here.  Stabilizers which preclude protein-protein interactions and 
surfactants which exclude proteins from the air-water interface would be expected to 
be less important in this case because the proteins will generally be adsorbed to an 
aluminum salt adjuvant (see below).  A GRAS (generally regarded as safe) list of 
stabilizers was compiled for screening the proteins discussed here and included amino 
acids, antioxidants, cyclodextrans, carbohydrates, surfactants, polyols and proteins. 
  As has been alluded to previously, most sub-unit vaccines require an adjuvant 
to boost the immune response.  Adjuvants boost the immune system response through 
a number of mechanisms including binding Toll-like receptors on antigen presenting 
cells, creating a depot from which antigen is released over time and inducing 
inflammation.138  Some antigens are capable of eliciting both humoral and cellular 
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immune responses while others only actively stimulate one branch.  It is no yet clear 
for the proteins investigated here what kind of immune response will afford the most 
protection.  LcrV and PcrV belong to bacteria which cause systemic, extracellular 
infection.  For these, a strong antibody response may be the most important factor in 
protection.  Studies in which humoral immunopotentiators were included in LcrV and 
PcrV trials support this assumption.  Studies of long term protection, however, using 
attenuated whole cell vaccines suggested that the cellular immune response was 
important in generating memory cells and thus long term protection.113  Shigella 
flexneri invades the intestinal mucosa and is primarily an intracellular pathogen.  It 
has been shown that IgA production limits the severity and spread of S. flexneri 
infections presumably by preventing bacterial entry at the apical membrane of the 
intestinal cells.79  With a subunit vaccine containing O polysaccharides as the antigen, 
protection was conferred with serum IgG levels correlating with protection (or at least 
mediation).82,83  While it is possible that the IgG itself was protecting, it seems more 
likely that IgG  mirrored IgA concentration which actually afforded the critical 
protection.   
 The adjuvant chosen for the studies presented in chapters 3 and 4 is the 
aluminum salt adjuvant, Alhydrogel®.  This adjuvant elicits a strong humoral 
response.138  The exact mechanism of its immune system stimulation is not known but 
it is possibly the result of a depot effect.139  This adjuvant was chosen because it is 
one of only a handful approved by the FDA and has a good safety record.  LcrV and 
PcrV, adsorbed to aluminum salt adjuvants, successfully protected mice in challenge 
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studies.  IpaD and SipD have not been administered in conjunction with this adjuvant 
class until now.  In fact, little is know about SipD’s antigenicity compared with the 
other proteins discussed above.  BipD may still prove to be an effective antigen 
despite the results of the studies discussed previously.  Future work will be needed to 
ascertain if an aluminum adjuvant is successful in producing a protective immune 
response or whether the use of alternative adjuvants needs to be explored.   
 
1.7   Chapter overviews 
 
Chapter 2 presents a biophysical characterization of the five tip proteins IpaD, 
BipD, SipD, LcrV and PcrV.  The temperature and pH response of these proteins are 
compared using EPDs and based on these results the tip proteins are classified into 
two sub-families.  The first sub-family contains IpaD, BipD and SipD whle the 
second is comprised of LcrV and PcrV.  This characterization comprises the pre-
formulation aspect of the potential vaccine(s).   
The immunogenicity of IpaD and SipD adsorbed to Alhydrogel® as measured 
by IgG antibody titers is described in Chapter 3.  Immune response to monomer 
needle proteins is also explored.  These antigens are tested in 1, 10 and 50 μg doses 
and when co-administered with their TTSS counterparts.  The tip proteins elicited a 
strong humoral immune response even in low quantities.  The presence of needle 
protein showed no effect.   
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Chapter 4 discusses the formulation of the five tip proteins from Chapter 1.  
Excipient screening and optimization are detailed.  In addition, aluminum salt 
adjuvant binding studies are discussed as well as adjuvant effects on stability.  Long 
term stability studies monitoring physical and chemical degradation are presented and 
evaluated.  From these tests, the formulation is shown to inhibit chemical 
degradation. 
Chapter 5 presents biophysical studies of a newly discovered putative TTSS 
tip protein from Chlamydiae (CT584).  EPDs and individual spectroscopic data are 
compared to known tip proteins.  In addition, analytical ultracentrifugation in both 
sedimentation and equilibrium modes reveals that CT584 oligomerizes in solution.   
Finally, Chapter 6 summarizes the conclusions from the previous chapters.  
Future work and implications of the data from TTSS proteins presented here are 
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2.1   Introduction 
 
 Gram-negative bacteria are responsible for some of the most serious 
epidemics in history and continue to cause serious outbreaks in modern times.  These 
bacteria cause conditions such as gastroenteritis (Salmonella typhimurium, Yersinia 
enterocolitica), septicemia (Salmonella typhi, Pseudomonas aeruginosa and Yersinia 
Pestis), lesions (P. aeruginosa), bacillary dysentery (Shigella flexneri) and 
melioidosis (Burkholderia pseudomallei).  Common among these bacterial pathogens 
is the use of a type III secretion system (TTSS),1 which ultimately transports proteins 
from the bacterium to the membrane and cytoplasm of targeted eukaryotic host cells 
to initiate bacterial infection.1,2  The TTSS operates through a molecular needle 
comprised of repeating units of a protein connected to a basal body which spans the 
inner and outer bacterial membranes.1-3  The external needle and basal body are 
referred to as the type III secretion apparatus (TTSA).  Through this nanomachine, 
the translocator proteins are inserted into the host cell membrane to form a pore 
through which effectors subsequently pass into the host cell cytoplasm to subvert 
normal cellular processes.1,2   
Recently, it was shown that invasion plasmid antigen D (IpaD) of S. flexneri 
localizes to the tip of the TTSA to control IpaB and IpaC secretion.4  IpaB and IpaC 
form a translocon pore in the host cell membrane permitting the passage of effector 
proteins into the host cell cytoplasm.5  IpaB and IpaC also induce cytoskeletal 
rearrangements in epithelial cells and apoptosis of macrophages.5-7  LcrV in Y. 
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enterocolitica also localizes to the tip of the TTSA, therefore it may function 
analogously.8  Antibodies to either LcrV or IpaD inhibit pore formation.4,9  BipD 
from B. pseudomallei will localize to the Shigella TTSA10 while PcrV from P. 
aeruginosa does the same in Yersinia TTSA.8  The similarity of the response of SipD 
from S. typhimurium to temperature and pH, compared to IpaD and BipD, described 
below suggest that it also may localize to the tip of the TTSA.   
Based on sequence homology and the conformational responses to pH and 
temperature reported here, the tip protein family can be divided into two sub-families.  
The IpaD sub-family consists of IpaD, BipD and SipD which have >25% sequence 
similarity overall and >90% similarity at the C-termini.11-13  The crystal structures of 
BipD and IpaD have been solved. They are dumbbell shaped, possessing a coiled-coil 
that separates the N and C-terminal domains.13  Studies of SipD also suggest the 
existence of two domains separated by a coiled-coil segment.14  LcrV and PcrV 
belong to a second sub-family of tip proteins.15  The LcrV crystal structure also 
displays a dumbbell shape16 and it is likely that PcrV has a structure and function 
similar to LcrV.8,15  All five of these proteins possess high helical content based on 
far-UV CD consistent with high resolution structural data.14,17   
The purpose of this chapter is to systematically examine these five proteins 
with the goal of seeking common structural features that might be related to their 
regulatory functions.  Some limited stability data exists for these tip proteins at pH 
7.4.14,17  It is probable, however, as discussed below, that these proteins encounter 
other pH conditions either in the gastrointestinal tract (in the case of S. flexneri, S. 
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typhimurium and Y. enterocolitica) or in pH microenvironments near cell membrane 
surfaces.18,19  Thus, elucidating the conformation and stability of these proteins in 
different pH environments may reveal significant aspects of their functional 
relationships to each other. The results from the various analyses are summarized 
using empirical phase diagrams (EPDs).20  The EPDs presented below display 
structural differences in proteins as a function of environmental variables of pH and 
temperature using color to provide an intuitive picture of molecular behavior.  It has 
been demonstrated that such diagrams can reveal structural similarity related to 
function, even in the absence of sequence homology.21 
 
2.2   Materials and Methods 
2.2.1.   Materials 
Details of plasmid preparation and affinity purification of recombinant 
proteins are described previously.14,15,17,22  The proteins were dialyzed in 20 mM 
citrate/20 mM phosphate buffer at pH 7 and then stored at -80 °C.   
 
2.2.2   Sample Preparation   
The samples were diluted to 0.14 mg/mL for UV absorption, CD and ANS 
fluorescence assays.  The same concentration was used for intrinsic fluorescence 
studies except when collecting light scattering data where the concentrations were 
reduced to 0.07 mg/ml.  The concentration of each sample was confirmed using UV 
absorption spectroscopy.23  The samples were diluted in buffers at the desired pH 
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value.  The dilution factor for all samples was at least 1:10 (in most cases 1:40).  The 
final pH for each sample was then confirmed.  
 
2.2.3   Ultraviolet Absorption Spectroscopy  
An Agilent 8453 diode-array spectrophotometer in conjunction with a peltier 
temperature controller was used to obtain ultraviolet (UV) absorption spectra.  
Spectra for each protein were examined from 200-400 nm.  The experimental 
resolution of each spectrum was 1 nm.  The spectra were recorded over a temperature 
range of 10-90 °C at intervals of 2.5 °C.  The optical density at 350 nm (OD350nm) was 
similarly monitored over the same temperature range.  The sample was incubated for 
5 min at each temperature to ensure equilibrium (i.e. no further spectral change).  The 
resulting spectra were analyzed using Agilent UV-visible ChemStation™ software 
using a fifth degree Savitzky-Golay polynomial after a 9 point filter to calculate the 
second derivative spectra.20  The derivative spectra were then fit to a cubic function 
with 99 interpolated points.  This provides an effective 0.01 nm resolution.   
 
2.2.4   Far-UV circular dichroism   
A Jasco J-720 spectrometer equipped with a peltier temperature controller 
(Tokyo, Japan) was used for far-UV circular dichroism (CD) analysis.  CD spectra 
were obtained for each sample at 20 °C with a resolution of 0.1 nm at 20 nm/min.  
CD signals at 222 nm were monitored from 10 to 85 °C at a rate of 15 °C/hr to 
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measure changes in α-helical content with respect to temperature.  CD signals were 
then converted to molar ellipticity using Microsoft® Excel 2002. 
   
2.2.5   Trp fluorescence   
Fluorescence spectra for both intrinsic and extrinsic fluorescence were 
collected using a PTI QM-1 spectrofluorimeter with a four cell position holder 
(Brunswick, NJ).  The temperature of the cuvettes was controlled using a circulating 
water bath.  The cuvettes used were quartz and had a 1 cm pathlength.  For Trp 
fluorescence studies, the samples were excited at 295 nm (>95% Trp emission).  
Emission spectra were collected from 290-400 nm with resolution of 1 nm using 1 s 
of signal integration per point.  Light scattering was measured by monitoring the 
intensity of the light at 295 nm at 180° from the fluorescence photomultiplier tube.  
Analysis was performed from 10 to 87.5 °C at 2.5 °C increments.  A spectrum of 
citrate-phosphate buffer alone was subtracted from the sample spectra.  Peak 
positions were calculated in Origin® by fitting the data to a 2° polynomial curve 
followed by a first derivative calculation.   
 
2.2.6   ANS fluorescence   
ANS was added from a 2 mg/ml ethanol solution to the sample to reach a 10:1 
ANS/protein ratio.  Samples were excited at 372 nm with emission spectra collected 
between 400 and 600 nm.  Each spectrum was subtracted with a spectrum of buffer 
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and ANS alone at the corresponding temperature.  Peak positions were obtained as in 
the Trp fluorescence analyses. 
 
2.2.7   Empirical Phase Diagrams   
The theory and mathematics underlying EPDs are covered in detail 
elsewhere.20  At a given pH and temperature, data were combined from multiple 
techniques to create multi-dimensional vectors (each technique representing one 
dimension).  Vectors were formed for all pH\temperature values and assembled to 
produce a density matrix.  Eigenvectors and eigenvalues were calculated from the 
matrix.  The three largest eigenvalues were used to create eigenvectors which would 
expand a truncated form of the data set to only three dimensions.  These newly 
constructed vectors can be plotted as a combination of three colors (red, green and 
blue).  Data from CD molar ellipticity at 222nm, the Trp fluorescence emission peak 
wavelength and intensity, light scattering, ANS emission peak wavelength and 
intensity, second derivative UV absorption negative peaks at 253, 259, 279, 284 and 
291 and optical density at 350 nm as a function of temperature and pH were included 
to construct the EPDs. 
 
2.3   Results 
2.3.1   IpaD   
All spectra displayed double minima at 208 nm and 222 nm at 20 °C (not 
illustrated), indicating substantial α-helical content.24  This is consistent with a 
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previous study which estimated the percentage of α-helical structure to be 50% at pH 
7.4.17  Peak minima are most intense at pH 3 and smallest at pH 5 suggesting loss of 
secondary structure.  The differences in peak intensity at 20 °C for 222 nm are seen in 
Figure 2.1A.  The molar ellipticity of IpaD was measured from 10 to 85 °C in 2.5 °C 
increments at 222 nm to monitor changes in secondary structure (Figure 2.1A). Upon 
exposure to increasing temperature, two distinct thermal transitions are observed at 
pH 3.  The onset temperature for the first transition is near 20 °C while the second 
begins at about 60 °C.  At pH 4 and 5 only one broad transition occurs.  Two 
transitions appear at pH 6-8 with the transitions occurring near 47 °C and 72 °C 
indicating greater stability under these pH conditions.   
 Intrinsic Trp fluorescence was recorded over the same pH range as that for 
CD to follow changes in tertiary structure of IpaD which possesses four Trp 
residues.25  The initial peak positions at all pH values except 3 are very similar (ca. 
329 nm) indicating the Trp residues are in comparable environments, which on 
average are relatively apolar (Figure 2.1B).  At pH 3 the peak position at 10 °C is 333 
nm which suggests the Trp residues are more solvent exposed.  Biphasic thermal 
transitions are evident for pH 3 with the red shift of both transitions indicative of 
protein unfolding.  At pH 4, a single red shifted transition is seen followed by a slight 
blue shift.  Transitions at pH 5 and 6 are to shorter wavelengths and occur near 35 °C.  
These blue shifts precede considerable variability in individual peak values and 
greater uncertainty.  This variability is probably due to aggregation. This conclusion 
is supported for pH 6 by both light scattering results obtained by measuring signal at 
 43














































































Figure 2.1.  IpaD spectroscopic data.  Far-UV CD molar ellipticity at 222 nm was 
monitored from 10 to 85 °C (A).   Intrinsic Trp fluorescence emission peak position 
wavelength (B) and light scattering intensity at 295 nm (C) were measured from 10 to 
87.5 °C.  The excitation wavelength for Trp fluorescence is 295 nm.  ANS 
fluorescence emission peak intensity (D) was measured from 10 to 87.5 °C.  The 
excitation wavelength was 372 nm.  ANS fluorescence peak intensity data were 
normalized to the intensity at 10 °C.  Error bars are the standard deviation from at 
least three trials.  , pH 3; , pH 4; ▲, pH 5; , pH 6; , pH 7; , pH 8. 
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the excitation wavelength (295 nm) and turbidity data recorded at 350 nm during UV 
absorbance measurements (Figures 2.1C, 2.2C).  The light scattering signal is 
saturated at pH 5; however, turbidity data are in agreement.  Aggregation at pH 5 and 
6 is not surprising given an isoelectric point (pI) of 5.55 for IpaD.  For pH 7 and 8, 
biphasic transitions are evident similar to those at pH 3 (Figure 2.1B).  Intrinsic Trp 
fluorescence peak intensity was also recorded for all five tip proteins but generally 
did not display any transitions not seen in the other techniques presented here. 
 The structure of IpaD was also probed using an extrinsic ANS probe.  ANS 
molecules typically bind to apolar regions of molecules and increasingly fluoresce in 
response to such binding events.26  Because of the negative charge on the dye, there 
may also be some electrostatic interactions with oppositely charged regions of 
proteins,27 especially at low pH.  Fluorescence wavelength positions were recorded 
with ANS dyes; however, the results exhibited little temperature dependence for any 
of the tip proteins being presented.  The intensity data provided clearer trends despite 
the small scale of the transitions (Figure 2.1D).  It is commonly postulated that when 
proteins unfold, ANS is able to bind to more apolar sites resulting in an increase in 
fluorescence.  At pH 3, a spike in intensity occurs near the same temperature as the 
second transition seen in both the Trp fluorescence and CD studies.  Transitions at pH 
4-6 appear to reflect aggregation events since the onset temperatures of aggregation 
seen in static light scattering measurements are nearly identical to those observed in 
ANS fluorescence.  Unlike pH 3, at pH 7 and 8 the transitions correspond to the first 
of the two thermal events observed in intrinsic fluorescence.  
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In addition to intrinsic Trp fluorescence, the IpaD tertiary structure was 
monitored using second derivative UV absorption spectroscopy.  All three aromatic 
side chains in a protein can be monitored using this technique to provide a more 
global picture of tertiary structural changes.28-30  IpaD has six Phe residues and ten 
Tyr residues in addition to the four Trp residues.25  Shifts to shorter wavelengths in 
second derivative UV absorption spectroscopy indicate movement to a more polar 
environment.  For the five recombinant proteins studied here, it is possible to resolve 
6-8 major negative peaks using second derivative UV absorption spectroscopy.  In 
this case, two peaks were selected for presentation which were consistently 
identifiable at all temperature and pH conditions.  These peaks were a Tyr signal at 
284 nm and a Trp minimum at 291 nm.  Two Phe peaks are also present at 253 and 
259 nm but these peaks were often independent of temperature and provided little 
new information.  Simultaneous with measuring peak position, the optical density at 
350 nm (OD350 nm) was recorded to detect possible temperature-induced aggregation.   
 In the case of the Tyr peak at 284 nm, the blue shifts for pH 3 and 4 have 
onset temperatures of 55 °C and 57 °C respectively (Figure 2.2A). The trend at pH 4, 
however, shows some attenuation of the blue shift and large uncertainty probably due 
to moderate aggregation.  Red shifts accompanied by increased uncertainty in peak 
positions at pH 5 and 6 suggest aggregation as well.  At pH 7 and 8, shifts to shorter 
wavelength at 65 °C agree with trends seen in both Trp fluorescence peak position 
and ANS fluorescence intensity.  Almost identical trends occur for the peaks at 291 
nm with blue shifts at all pH values with the exception of pH 4-6 which displays a red  
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Figure 2.2.  IpaD second derivative UV absorption spectroscopy.  Absorption 
peak position minima centered around 285 nm (Tyr, A) and 291 nm (Trp, B) are 
recorded as a function of temperature from 10 to 90 °C.  Optical densities at 350 nm 
(C) are recorded over the same temperature range.  Error bars are the standard 
deviation from at least three trials.  , pH 3; , pH 4; ▲, pH 5; , pH 6; , pH 7; 




shift at pH 4 immediately preceded by a small transition to shorter wavelengths 
(Figure 2.2B).  Unlike CD and intrinsic fluorescence measurements which display 
multiple transitions, only one transition is clearly defined for transitions seen in most 
second derivative UV absorption spectroscopy melting curves.  The turbidity data as 
measured by optical density at 350 nm agrees with the previously described light 
scattering data in that the major transitions indicative of aggregation occur at pH 5-6.  
The OD350 nm data do not show any transition at pH 4 in contrast to right-angle light 
scattering reflecting the greater sensitivity of the latter. 
 
2.3.2   BipD   
The same conditions which were applied to IpaD were used for measurements 
taken of BipD and the three remaining proteins.  Far-UV CD spectra of BipD from 
190-260 nm display the characteristic double minima at 208 and 222 nm of α-helices 
(not illustrated). This is expected based on the high resolution X-ray structure of 
BipD which shows 59% α-helical content.13  There is little variation in intensity of the 
two peaks with respect to pH at low temperature.  Monitoring the CD spectra 
intensity at 222 nm shows a single thermal transition for BipD occurring at each pH 
which transpires at significantly higher temperatures than those seen for IpaD or other 
tip protein studied here (Figure 2.3A).  The transition at pH 3 begins at 32 °C and is 
fairly broad.  At pH 4, the transition begins at 65°C and is sharper than at pH 3 and 
ends at about 80 °C.  Transitions at pH 5-8 do not begin until at least 75°C and are 
more abrupt.   
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Figure 2.3.  BipD spectroscopic data.  Far-UV CD molar ellipticity at 222 nm was 
monitored from 10 to 85 °C (A).   Intrinsic Trp fluorescence emission peak position 
wavelength (B) and light scattering intensity at 295 nm (C) were measured from 10 to 
87.5 °C.  The excitation wavelength for Trp fluorescence is 295 nm.  ANS 
fluorescence emission peak intensity (D) was measured from 10 to 87.5 °C.  The 
excitation wavelength was 372 nm.  ANS fluorescence peak intensity data were 
normalized to the intensity at 10 °C.  Error bars are the standard deviation from at 












































































Figure 2.4.  BipD second derivative UV absorption spectroscopy.  Absorption 
peak position minima centered around 279 nm (Tyr/Trp, A), 285 nm (Tyr, B) and 291 
nm (Trp, C) are recorded as a function of temperature from 10 to 90 °C.  Optical 
densities at 350 nm (D) are recorded over the same temperature range.  Error bars are 
the standard deviation from at least three trials.  , pH 3; , pH 4; ▲, pH 5; , pH 




Similar to CD measurements, transitions seen in intrinsic Trp fluorescence 
begin primarily after 70 °C for peak position data (Figure 2.3B).  Also, like IpaD, the 
peak positions shift to longer wavelengths at high temperatures indicating the four 
Trp residues31 are entering a more polar environment except at pH 5 and 6.  At pH 5, 
an initial blue shift occurs at approximately 67 °C followed by a larger red shift 
beginning at 77 °C.  While the transition at pH 4 is primarily a shift to longer 
wavelengths, it appears attenuated by possible aggregation as suggested by the large 
increase in error values.32 This is confirmed by both light scattering and turbidity data 
(Figures 2.3C and 2.4D).  Light scattering and OD350 nm measurements for BipD 
reveal that significant aggregation occurs, primarily at pH 5 and 6.  BipD has a pI of 
5.04, which is consistent with the aggregation and precipitation observed under these 
conditions.  
 Transitions in ANS fluorescence peak intensity data also occur primarily after 
70 °C (Figure 2.3D).  The earliest transition is at pH 3 with an onset temperature of 
37 °C.  These results agree with those observed in either the temperature dependent 
CD or intrinsic fluorescence experiments.  What is apparent from results produced by 
all of these techniques is the high stability of BipD compared to the other tip proteins 
except at low pH. 
 In addition to the two negative second derivative peaks shown above for IpaD, 
a Tyr/Trp peak at 279 nm was also resolved with BipD and the other tip proteins.  
BipD contains four Trp, six Phe (peaks not illustrated) and six Tyr residues.31  The 
negative Tyr/Trp (279 nm) peak displays shifts to shorter wavelengths at all pH 
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conditions (Figure 2.4A).  The negative Tyr peak at 284 nm shows transitions to 
shorter wavelengths for all pH environments except pH 5 (Figure 2.4B).  The same is 
true for the Trp peak around 291 nm (Figure 2.4C) with it moving to longer 
wavelengths at both pH 5 and 6.  The reason for the differences in trends at pH 6 
between Figures 2.4B and 2.4C is not clear. Nevertheless, red shifts at pH 5 and 6 are 
consistent with data from the other techniques.  The blue shifts present in Figure 2.4A 
suggest that some of the buried Tyr and Trp residues in BipD may be moving into 
more aqueous environments despite aggregation which might be expected to bury the 
aromatic side chains.   
  
2.3.3   SipD  
This protein also displays helix rich CD spectra (not illustrated) with the 208 
and 222 nm peaks most intense at pH 4 and smallest at pH 6.  A previous study 
estimated the percentage of α-helical structure to be 55%.14  The differences in peak 
intensities observed across the spectra can be seen at 10 °C in Figure 2.5A.  Molar 
ellipticity of SipD measured at 222 nm from 10 to 85 °C shows biphasic transitions 
for all pH conditions with the lowest onset temperatures at pH 3 (Figure 2.5A).   
 Intrinsic Trp fluorescence shows thermally induced conformational changes 
and aggregation (Figure 2.5B-C).  Changes in peak position manifest low and high 
temperature transitions for all pH values, with the second transitions at pH 4-6  
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Temperature (Co)  
Figure 2.5.  SipD spectroscopic data.  Far-UV CD molar ellipticity at 222 nm was 
monitored from 10 to 85 °C (A).   Intrinsic Trp fluorescence emission peak position 
wavelength (B) and light scattering intensity at 295 nm (C) were measured from 10 to 
87.5 °C.  The excitation wavelength for Trp fluorescence is 295 nm.  ANS 
fluorescence emission peak intensity (D) was measured from 10 to 87.5 °C.  The 
excitation wavelength was 372 nm.  ANS fluorescence peak intensity data were 
normalized to the intensity at 10 °C.  Error bars are the standard deviation from at 









































































Temperature (Co)  
Figure 2.6.  SipD second derivative UV absorption spectroscopy.  Absorption 
peak position minima centered around 279 nm (Tyr/Trp, A), 285 nm (Tyr, B) and 291 
nm (Trp, C) are recorded as a function of temperature from 10 to 90 °C.  Optical 
densities at 350 nm (D) are recorded over the same temperature range.  Error bars are 
the standard deviation from at least three trials.  , pH 3; , pH 4; ▲, pH 5; , pH 





indicating aggregation.  At pH 4-6, the initial red shifts are followed by transitions 
that appear either as blue shifts or as attenuated shifts to longer wavelength with 
increased uncertainty in peak position values.  Increases in both light scattering and 
turbidity indicate these trends are caused by aggregation (Figures 2.5C, 2.6D).  As 
seen with BipD, the pI of SipD is near 5 suggesting that pH 5 and 6 is where 
insoluble aggregation would be expected.  Extrinsic fluorescence employing ANS 
shows a transition in intensity at pH 3 corresponding to the second transitions 
observed by other techniques (Figure 2.5D).  While no clear shift is visible at pH 4, 
pH 5 exhibits a transition at the temperature of protein aggregation.  Biphasic 
transitions are visible at pH 6-8 in agreement with Trp fluorescence and CD thermal 
results.  
 SipD contains eleven Tyr, seven Phe (peaks not illustrated) and four Trp 
residues.33  The Tyr/Trp peak at 279 nm manifests temperature-dependent blue shifts 
under most pH conditions suggesting movement to more polar environments (Figure 
2.6A).  Almost identical trends occur for the peaks at 285 and 291 nm with transitions 
to shorter wavelengths except at pH 4 and 5 (Figures 2.6B-C) in agreement with the 
other techniques.  The OD350 nm data shows the greatest aggregation at pH 5 with 
some occurring at pH 6 as well (Figure 2.6D).  Unlike the right-angle light scattering 





2.3.4   LcrV 
Far-UV CD spectra of LcrV at pH values from 3-8 show the characteristic 
negative peaks at 208 nm and 222 nm (not illustrated).  This is again expected since 
the α-helical content estimated from a previous CD study is 68%.14  CD spectra at pH 
3 and 4 have more intense negative peaks implying greater secondary structure (see 
Figure 2.7A at 10 °C).  The magnitudes of the peaks at pH 5-8 are within 0.5×10-9 
deg cm2/dmol of each other suggesting similar secondary structure content.  The 
molar ellipticity of LcrV monitored at 222 nm from 10 to 85 °C shows transitions 
with onset temperatures which increase with increased pH with the exception of pH at 
7 and 8 where the transition temperatures are nearly identical (Figure 2.7A).  Only 
one transition appears at each pH from pH 5-8.  At pH 3 and 4 however, some high 
temperature transitions may be occurring near 80 °C.   
The intrinsic Trp fluorescence of LcrV as a function of temperature shows 
shifts to lower wavelengths in fluorescence peak position at all pH conditions 
accompanied by increased light scattering (Figures 2.7B-C).  The blue shifts seen in 
Figure 2.7B mark significant divergence from trends in the first three tip proteins 
where such transitions generally only occurred at pH 5 and 6.  The temperature of the 
transition rises with increased pH.   While the transitions are occasionally difficult to 
see in Figure 2.7C, close inspection of the results at pH 3 and 8 indicate that these pH 
conditions follow the trends detected by the other techniques.  The magnitude of the 
light scattering changes at pH 4-6 as well as the precipitation at pH 5 is explainable 
by the pI of 5.49. Unlike light scattering, OD350 nm measurements only display clear  
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Figure 2.7.  LcrV spectroscopic data.  Far-UV CD molar ellipticity at 222 nm was 
monitored from 10 to 85 °C (A).   Intrinsic Trp fluorescence emission peak position 
wavelength (B) and light scattering intensity at 295 nm (C) were measured from 10 to 
87.5 °C.  The excitation wavelength for Trp fluorescence is 295 nm.  ANS 
fluorescence emission peak intensity (D) was measured from 10 to 87.5 °C.  The 
excitation wavelength was 372 nm.  ANS fluorescence peak intensity data were 
normalized to the intensity at 10 °C.  Error bars are the standard deviation from at 













































































T em pe ra tu re  (C o )  
Figure 2.8.  LcrV second derivative UV absorption spectroscopy.  Absorption 
peak position minima centered around 279 nm (Tyr/Trp, A), 285 nm (Tyr, B) and 291 
nm (Trp, C) are recorded as a function of temperature from 10 to 90 °C.  Optical 
densities at 350 nm (D) are recorded over the same temperature range.  Error bars are 
the standard deviation from at least three trials.  , pH 3; , pH 4; ▲, pH 5; , pH 





transitions at pH 5 and 6 (Figure 2.8D).  Employing the ANS probe, the relative peak 
intensity data has the same temperature transition trends seen by the other techniques, 
except at pH 3 for which transitions occur later than pH 4 (Figure 2.7D).  
Second derivative UV absorption spectroscopy of LcrV partially supports the 
trends seen in tertiary structure behavior by the fluorescence techniques (Figures 
2.8A-C).  LcrV contains a single Trp, eleven Phe (peaks not illustrated) and eleven  
Tyr residues.34  The peak at 279 nm at pH 7 and 8 shows transitions to shorter 
wavelength (Figure 2.8A).  The behavior of these transitions is not in complete 
agreement with the intrinsic Trp fluorescence or the Trp second derivative negative 
data near 290 nm (Figure 2.8C).  The negative peak for Tyr at 285 nm also shows 
transitions to shorter wavelengths at pH 7 and 8 (Figure 2.8B).  This is possible since 
residues may enter a more polar environment despite aggregation.  The second 
derivative peak at 290 nm is, however, in direct agreement with the intrinsic 
fluorescence data.  The turbidity results only show significant transitions at pH 5-6 
(Figure 2.8D). 
   
2.3.5   PcrV  
The far-UV CD spectra of PcrV are similar to those of the other proteins (not 
illustrated).  The low pH environments at 3 and 4 elicit the most intense negative 
peaks again suggesting increased helical content.  The peaks at pH 6 are the least 
intense indicating far less secondary structure.  Measuring the intensity of the 
negative peak at 222 nm as a function of temperature produces transitions which  
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T em perature (Co)  
Figure 2.9.  PcrV spectroscopic data.  Far-UV CD molar ellipticity at 222 nm was 
monitored from 10 to 85 °C (A).   Intrinsic Trp fluorescence emission peak position 
wavelength (B) and light scattering intensity at 295 nm (C) were measured from 10 to 
87.5 °C.  The excitation wavelength for Trp fluorescence is 295 nm.  ANS 
fluorescence emission peak intensity (D) was measured from 10 to 87.5 °C.  The 
excitation wavelength was 372 nm.  ANS fluorescence peak intensity data were 
normalized to the intensity at 10 °C.  Error bars are the standard deviation from at 











































































Temperature (Co)  
Figure 2.10.  PcrV second derivative UV absorption spectroscopy.  Absorption 
peak position minima centered around 279 nm (Tyr/Trp, A), 285 nm (Tyr, B) and 291 
nm (Trp, C) are recorded as a function of temperature from 10 to 90 °C.  Optical 
densities at 350 nm (D) are recorded over the same temperature range.  Error bars are 
the standard deviation from at least three trials.  , pH 3; , pH 4; ▲, pH 5; , pH 





occur successively earlier as pH decreases (Figure 2.9A).  The transitions at pH 5 and 
6 are the sharpest with the onset temperature of pH 5 near 45 °C.  The magnitude of 
the intensity change is comparable for all pH environments.   
The intrinsic Trp fluorescence of PcrV displays different temperature/pH 
behavior than that seen for SipD, BipD or IpaD but very similar to trends exhibited by 
LcrV.  At pH 3 and 4, low temperature transitions (about 20 and 27 °C, respectively) 
involve shifts to longer wavelengths although the early transition at pH 4 is followed 
by a shift to shorter wavelengths (Figure 2.9B).  In the case of all other pH 
conditions, blue shifts occur indicating that the four Trp residues35 move on average 
into a more non-polar environment.  As observed with the far-UV CD results, higher 
transition temperatures appear to be directly related to increased pH.  Light scattering 
(Figure 2.9C) shows the same pH/temperature relationship for pH 5-8 with some 
increase in light scattering also visible at pH 4 at higher temperatures.  Extrinsic ANS 
fluorescence relative intensity in the presence of PcrV from 10 to 87.5 °C shows a 
small early shift at pH 3 (Figure 2.9D).  The transitions in peak position for the other 
pH values vary directly with pH.  This trend is in agreement with both far-UV CD 
and intrinsic Trp fluorescence temperature studies.   
  Second derivative UV absorption spectroscopy results for PcrV were not 
conclusive for all peaks (Figure 2.10A-C).  PcrV contains three Trp, one Tyr and 
eight Phe (not illustrated) residues.35  The peaks around 279 and 285 nm show similar 
trends (Figure 2.10A-B).  Blue shifts are evident at pH 3 and 4 while red shifts appear 
to occur at pH 5-7.  At pH 8, both peaks exhibit a transition to shorter wavelengths 
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implying movement into a more polar environment beginning at 55 °C.  In the case of 
the Trp peak at 291 nm, no discernable transitions can be resolved (Figure 2.10C).  At 
higher temperatures, the peak position appears to fluctuate erratically with sufficient 
error to make analysis of the average local environment of the 3 Trp residues 
impossible.  Turbidity data measured by optical density at 350 nm agree well with the 
right-angle light scattering observed during the intrinsic Trp fluorescence studies 
(Figure 2.10E). 
 
2.3.6   Empirical Phase Diagrams   
An effective means to visually summarize data from a wide variety of 
different techniques into a single, intuitive form is by employing empirical phase 
diagrams (EPDs).20,32,36-38  The EPDs presented here show the effects of pH and 
temperature on proteins expressed in the form of colored region as a function of 
temperature and pH.  Each colored block is a vector representation of the results from 
all techniques at a given pH and temperature relative to the same measurements at all 
other temperature and pH conditions for the same protein.  Colors that are identical 
(or nearly so) indicate structural similarity.  Since these regions are empirically 
determined and no equilibrium is necessarily present between the different (non-
thermodynamic) states of the protein, they are referred to as empirical or apparent 
phases.  It should be noted that the colors in any particular phase diagram are 
arbitrarily selected because of the normalization process used to permit data 


































































































Figure 2.11.  Empirical phase diagrams of five tip proteins.  Empirical phase 
diagrams for IpaD (A), BipD (B) and SipD (C) show similar responses to pH and 
temperature.  LcrV (D) and PcrV (E) phase diagrams exhibit similar trends as well.  






An EPD for IpaD (Figure 2.11A) shows that the lower temperature regions at 
pH 4 and 7-8 have similar conformational states. At pH 7 two possible transitions 
appear with the initial change at about 35 °C and a second alteration at higher 
temperature.  As the first transition is a less pronounced change in color, the trend at 
pH 7 could be considered as one broad transition from 35-70 °C however the results 
from intrinsic Trp fluorescence and CD suggest two thermal events are occurring.  A 
transition begins at 25 °C at pH 4 and by 45 °C another conformation is evident.  
Even at low temperatures, the forms of IpaD at pH 5 and 6 are different from those at 
other pH values.  Widely fluctuating colors at high temperatures are characteristic of 
aggregation and precipitation.21,37 
The EPD for BipD displays an unexpected transition occurring under all pH 
conditions beginning at about 35 °C (Figure 2.11B).  This transition is not directly 
observable in the data of the various techniques except perhaps in the ANS 
wavelength fluorescence experiments.  When the ANS fluorescence data is removed 
however, the transition remains (not illustrated).  It is therefore possible that this 
effect is an artifact of the intrinsic temperature effect on the CD and fluorescence 
peaks.  Such results have been noted in studies of pure model amino acids using 
fluorescence and UV absorption spectroscopy and resultant temperature/pH EPDs.21, 
unpublished results  As seen with IpaD, at higher temperatures there are clear 
conformational differences between pH 5-6 and lower and higher pH.    
The empirical phase diagram for SipD shows evidence of conformational 
differences at pH 5 and 6 compared to the pH values at pH 4, 7 and 8 (Figure 2.11C).  
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As expected, at pH 3 the conformational state of SipD is also different.  Two 
temperature transitions are visible for most pH conditions with aggregation occurring 
at pH 4-6. The transitions at pH 7 occur near 45 °C and 75 °C.  The similarities in 
phase diagrams for IpaD and SipD indicate that both proteins respond analogously to 
pH and temperature.  Indeed the similarities between these two tip proteins and also 
BipD suggest clear structural and presumably functional differences between them 
and LcrV and PcrV 
The EPD for LcrV demonstrates fairly homogenous structural states at pH 5-8 
at different forms at pH 3-4 (Figure 2.11D).  As seen in the actual experimental data 
for the individual techniques, only a single temperature transition is visible which 
increases with increasing pH.   Both the conformational continuity from pH 5-8 and 
the relationship between pH and protein stability distinguish the EPD of LcrV from 
those of the IpaD sub-family. 
The EPD for PcrV, like that of LcrV, demonstrates a direct correlation 
between increasing pH and increasing transition temperature for pH values above pH 
4 (Figure 2.11E).  The multicolored regions at pH 5-7 are clear indicators of 
significant aggregation. Transitions are visible at pH 3 and 4 but are smaller than 






2.4   Discussion 
 
 In this study, the effects of pH and temperature on protein stability are probed 
by various spectroscopic techniques on a set of related proteins from pathogenic gram 
negative bacteria that are involved in regulating the activation of type III secretion.  
The large amount and complexity of the resultant data (not all shown) make simple 
interpretation difficult.  The data were therefore combined to create empirical phase 
diagrams that summarize the behavior of the proteins as a function of pH and 
temperature.  Based on both direct inspection of the spectroscopic data and the 
resultant phase diagrams, the five proteins appear to fall into two sub-families.  IpaD, 
BipD, and SipD have similar stability and aggregation patterns as seen by most 
spectroscopic methods and their phase diagrams.  In contrast, LcrV and PcrV show 
remarkably similar stability behavior, which are distinct from that of the IpaD sub-
family.  These results are not unexpected given the sequence homology shared by 
SipD, BipD and IpaD, especially near their C-termini.14  LcrV and PcrV also share 
considerable sequence homology.35  The empirical phase diagrams generated here 
illustrate the power of this form of data presentation in synthesizing information from 
a large number of disparate techniques in a form which provides clear, concise insight 
into shared protein temperature and pH stability behavior. 
 It was shown previously that IpaD and BipD possess N and C-terminal 
domains separated by a coiled coil which combine to form a dumbbell shaped 
structure.13,17  The putative structure of SipD is therefore expected to be similar.  For 
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IpaD and SipD at pH 7.4, the proteins are known to be comprised of two 
independently folding domains with the N-terminal domain more thermally labile.14,17  
Two thermal transitions are visible throughout much of the pH range used in this 
study for IpaD and SipD employing both CD and intrinsic Trp fluorescence 
spectroscopy.  The two transitions are not seen in the phase diagrams at pH 3 but are 
clearly visible from pH 4 through 8.  While there appear to be two transitions in the 
BipD phase diagram, the middle temperature range shows no major transitions in the 
individual spectroscopic data.  Studies of model aromatic amino acids show clear 
changes as a function of temperature and pH that in phase diagram form are similar to 
those seen in BipD (unpublished data). The probable reason for the single transition 
seen in BipD is an unusually stable N-terminal domain.  From x-ray diffraction 
structural analysis of BipD, the N-terminal region appears to have strong interaction 
with the coiled coil.10   The effect of this has also been observed by FTIR with BipD’s 
coil resembling a triple coiled coil.14  Because of this interaction, the N-terminal 
domain is stabilized such that there is only one major unfolding event for this protein.  
This interaction is not present in IpaD and unlikely to be present in the putative 
structure of SipD. 
The most striking feature of the three proteins in the IpaD sub-family is the 
pH dependent changes in structure.  The proteins manifest three distinct structural 
forms from pH 3 through 8.  The EPDs of IpaD and SipD at pH 5 and 6 show clear 
structural differences at all temperatures when compared to those seen at pH 4, 7 and 
8.  Less structural difference is observed for BipD at low temperatures, although 
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above approximately 45 °C a different structural form appears to be present.  While 
this difference at pH 5 and 6 could reflect proximity to their pI, since this is not seen 
in the LcrV subfamily, this conserved pH dependence suggests some possible 
common mechanistic function in all three tip proteins.  Little has been done 
previously with the TTSA to investigate possible pH effects.  Given, however, the 
dramatic pH differences in the gastrointestinal tract which S. flexneri or S. 
typhimurium is expected to encounter, the pH effects observed on the tip proteins may 
play an important role.  Additionally, a lower pH microenvironment often exists near 
cell membrane surfaces due to the negative surface charge attracting protons from the 
bulk solution.18,19  Such microenvironments have been suggested to be involved in 
modulating conformational states in other systems.19,39,40  Thus, these 
microenvironments might alter the structure of the IpaD sub-family in 
mechanistically significant ways as well. 
Unlike the IpaD sub-family of proteins, LcrV and PcrV do not exhibit two 
distinct thermal transitions.  The published LcrV crystal structure16 shows the 
dumbbell shape which appears to be a common feature of all tip proteins.10,13  Given 
the single observed temperature transition for LcrV and PcrV, the N-terminal region 
of these proteins is probably not an independently folding domain but rather its 
conformational integrity may be coupled to that of the C-terminal region.14  In 
contrast to the IpaD subfamily where the N-terminal domain has been proposed to act 
as a self-chaperone for the coiled-coil, the LcrV subfamily proteins possess an 
independent chaperone (LcrG or PcrG) which appears to interact with the coiled-
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coil.41,42  No definitive function has yet been attributed to the N-terminal portion of 
the LcrV subfamily as would be expected if it behaved as a separable domain. Thus, 
the N-termini of the two different subfamilies may not have the same function.    
Perhaps the most striking feature of these proteins is the pH dependence of 
their stability.  For both Lcrv and PcrV, as pH increases from 4-8, the transition 
temperature increases as well.  This trend leads to the characteristic stepped pattern 
present in the phase diagrams.  While this dependence might have some effect on 
LcrV in Y. enterocolitica as it encounters different pH conditions in the 
gastrointestinal tract, its significance is unclear.  Furthermore, as P. aeruginosa and Y. 
pestis (this species also possesses LcrV) invade through non-oral routes, the increase 
in stability with pH range may be more indicative of the advantage of greater stability 
for this sub-family near physiologic pH.  
Empirical Phase diagrams have previously been used to demonstrate structural 
similarities between proteins of similar function despite differences in primary and 
tertiary structure.21  LcrV and PcrV, known orthologs, also possess phase diagrams 
with very similar patterns.  From pH 5-8 at low temperature, the conformations are 
invariant for each.  At pH 3 and 4, their structures display large differences even at 
low temperature and from pH 5-8 they both aggregate with increasing pH and 
temperature.  Most striking in this study is the clear difference between the phase 
diagrams of the IpaD sub-family to those of the LcrV sub-family.  These differences, 
especially with regard to pH, suggest possible divergence in mechanisms between the 
sub-families.   
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Immunogenicity of Recombinant TTSS Proteins 
IpaD, MxiH, SipD and PrgI
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3.1   Introduction 
 
Gram-negative bacterial pathogens are responsible for millions of debilitating 
infections each year.  For example, Shigella flexneri and Salmonella spp., account for 
upwards of 165 and 200 million cases annually, respectively 1,2.  The Shigella species 
primarily use fecal-oral transmission to invade human hosts, most commonly via 
contaminated food or water.  Host-to-host spreading, however, has also been 
observed.  As a result, densely populated regions lacking proper sanitation are among 
the most heavily impacted.  Symptoms of infection include fever, vomiting, severe 
abdominal cramping and/or bleeding, diarrhea and dysentery.  Immuno-compromised 
populations, including the young and elderly, are more susceptible to serious 
complications arising from infection, which may ultimately result in death.  
Salmonella spp. also infects via the fecal-oral route with symptoms similar to those of 
Shigella; however, select serotypes are also known to induce bacteremia 3.  While 
Shigella infections are more common in developing nations, high profile Salmonella 
outbreaks are increasingly frequent in the U.S 4,5   
Due to the frequency and severity of disorders caused by gram-negative 
bacteria, and their prevalence in the developing world, an inexpensive efficacious 
vaccine is a leading priority.  This need is further emphasized by the emergence of 
antibiotic resistant strains over the last twenty years.  For instance, in separate studies 
of Shigella outbreaks in Kenya and Chile, resistance to Ampicillan was more than 
80% percent 6,7.  Also observed in Kenya, 47% of isolated Salmonella species were 
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resistant to at least 3 commonly used antibiotics 8.   In the developed world, drug 
resistance is also on the rise.  In the United States, the number of drug-resistant 
strains has risen from 0.6% to 34% in a sixteen year period 9.   
These two pathogens have in common Type Three Secretion Systems (TTSS) 
which facilitate host cell invasion.  TTSS complexes are composed of more than 20 
proteins organized in basal and extracellular regions which span the inner and outer 
bacterial membranes.  They protrude approximately 60 nm from the bacterial surface 
10,11.  The extracellular portion is commonly referred to as the ‘needle’ for its tubular 
geometry and involvement in transporting effector proteins directly from the bacterial 
interior to the host cell cytoplasm.  The needle is primarily composed of 
approximately 120 copies of a repeating polymeric unit arranged in a helical array 
10,11.  The subunit (MxiH, Shigella flexneri and PrgI, Salmonella spp.) is a small (9-10 
kDa) protein composed largely of alpha helical structure.  On the distal needle tip lies 
a multimer which regulates secretion of the effector proteins 12.  The monomer (IpaD, 
Shigella flexneri and SipD, Salmonella spp.) is a slightly acidic dumbbell shaped 
protein (35-37 kDa) with a coiled coil at its center 13,14.   
Here the focus is on the needle (MxiH and PrgI) and tip (IpaD and SipD) 
proteins as potential vaccine antigens due to their surface exposure and essential 
function during infection.  It is thought that antigens with repeating epitopes are more 
immunogenic than those possessing only a single recognition site 15.  Additionally, 
increased antigen size has been shown to increase immunogenicity.  For this reason, a 
recombinant polymeric needle construct was chosen for formulation which mimics 
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the TTSS structure.  This would be combined with tip proteins to create a vaccine 
with multi-valency and multi-epitope specificity. 
Vaccine research directed toward these two pathogens has primarily focused 
on employing lipopolysaccharide (LPS) and attenuated bacteria, with limited success 
16,17.  In general, vaccines for Salmonella have focused on prevention of enteric fevers 
such as typhoid, but little work has been done to combat non-typhoidal indications 
16,18,19.  In the case of Shigella, both an attenuated form of the bacteria as well as a 
formulation containing an O-polysaccharide linked to a carrier protein have reached 
Phase III clinical trials, but have not yet attained approval 17.  Significant work has 
also been done on IpaD, the tip protein from the Shigella system.  Several groups 
have shown IpaD to be immunogenic 20, and most recently that antibodies raised 
against IpaD neutralize host-cell invasion of Shigella in-vitro 12.  Furthermore, 
epitope mapping has been completed for IpaD, which indicates that immune 
responses are greater in the amino-terminal region 20.  In the same study, it was noted 
that the Salmonella analog, SipD, shares significant sequence homology with the C-
terminal region of IpaD.  Thus, it is possible that the epitopic response in these 
regions may provide a degree of cross-protection 20. 
Another bacterium for which vaccine efforts have focused on TTSS 
components is Yersenia pestis.  In this case, work has focused on subunit forms of the 
F1 capsular antigen and LcrV, the TTSS needle tip protein.  Both have been proven 
immunogenic and protective, although development has been slowed by several 
factors including a demonstrated immuno-suppressive effect of LcrV on innate 
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immunity 21-24.  Regardless, it has been established that LcrV activates dendritic cells 
(DCs) 25.  Similar to the work indicated here, the needle component, YscF, has also 
been considered as a vaccine antigen for this species.  The wild type needle protein 
was shown to elicit a strong antibody response, and provide a degree of protection 
(60%) upon challenge 26,27.  In contrast to the protective effect of antibodies to IpaD, 
anti-YscF does not inhibit translocation of effector proteins suggesting that its 
protective effect is probably due to opsinization and/or enhanced complement binding 
26. 
The work presented represents an initial attempt to develop human vaccines 
for two of these pathogens.  To this end, an approved adjuvant, Alhydrogel, was 
included in the proposed recombinant subunit formulations. 
 
3.2   Materials and Methods 
3.2.1   Vaccine 
Recombinant proteins were expressed in E. coli as described previously 28-31.  
The needle proteins (MxiH and PrgI) were expressed with a five residue C-terminal 
truncation to prevent inherent polymerization and ensure monomeric behavior.  
Additionally, MxiH was expressed in its full length form, resulting in largely 
polymerized material referred to as ‘Needle’ hereafter (data not shown).  All proteins 
were purified by means of a C-terminal His6 tag, and dialyzed to 10 mM Histidine, 
144 mM NaCl buffer at pH 6.0.  Proteins were adsorbed to Alhydrogel, a positively 
charged aluminum salt adjuvant, at a concentration of 0.5 mg/mL aluminum by 
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stirring at 4 oC.  In bivalent formulations, the solution materials were mixed, and the 
adsorption step was performed subsequent to mixing.  Characterization and analysis 
of each formulation are documented in chapter 4.  In all cases complete adsorption 
(>95%) of the antigens was observed. 
    
3.2.2   Animals and Immunization 
Animal studies were performed at the University of Kansas in accordance 
with regulations set forth by the Institutional Animal Care and Use Committee and 
guidelines of the Association for Assessment and Accreditation of Laboratory Animal 
Care.  For all experiments, BALB/c mice were acquired from Charles River Breeding 
Laboratory (Wilmington, MA) and quarantined for 7 days prior to study start.  
Inoculations (100 µL) were administered intramuscularly on study days 1, 14 and 28 
and mice were bled via the submandibular vein on days 0, 7, 21, 35 and 49.32  
Weights were recorded at each time-point and monitored for indications of adverse 
effects due to dosing, however none were observed.  Mice were euthanized following 
the final bleed on day 49.   
In the first study, each group contained 10 mice (5 female and 5 male) with 
the exception of the histidine buffer control group which contained only 7 mice.  No 
significant differences were observed in end-point titers between male and female 
mice.  Formulations containing only one antigen (MxiH or IpaD) were dosed at 1 
(M1, D1), 10 (M10, D10) and 50 (M50, D50) µg/dose, while formulations containing 
both antigens (MD1, MD10 and MD50) were administered at the same total protein 
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concentration (1, 10 and 50 µg protein/dose); containing one-half the amount of each.  
The two control groups were dosed with either formulation buffer or 0.5 mg/mL 
Aluminum in formulation buffer. 
Study 2 contained groups of 7 mice (female), and a single control group 
containing 5 mice (0.5 mg/mL Aluminum in isotonic His buffer).  MxiH, MxiH 
Needle and IpaD were all dosed separately at 10 µg, both in the formulation buffer as 
well as adsorbed to Alhydrogel (M-Soln, M-His, N-Soln, N-His, D-Soln and D-His 
respectively).  Bivalent formulations containing IpaD and either MxiH or Needle 
were administered adsorbed to Alhydrogel at total protein concentrations of 20 
µg/mL (10 µg of each). 
The third study, conducted concurrently with study 2, involved groups of 8 
mice, and a control group of 5 mice (0.5 mg/mL Aluminum in isotonic His buffer). 
Monovalent formulations of both PrgI and SipD were administered at 1, 10 and 50 
µg/dose (P1, P10, P50, S1, S10 and S50), while bivalent formulations were dosed at 
total protein concentrations of 2, 20 and 100 µg/dose (PS1, PS10 and PS50).  Non-
adsorbed formulations were also administered at 50 µg for PrgI, SipD and the 
bivalent combination (P50-Soln, S50-Soln and PS50-Soln). 
     
3.2.3   IgG Detection in Serum Samples 
Antigen specific IgG titers were determined for individual sera samples using 
a standard Enzyme Linked Immunosorbent Assay (ELISA).  The optimal protocol 
differed for the needle (MxiH and PrgI) and tip (IpaD and SipD) proteins.  Needle 
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proteins were adsorbed (100 µL) onto Nunc-Immuno™ MediSorp™ (Nalge Nunc 
International, Wiesbaden, Germany) 96-well plates at 10 µg/mL in carbonate buffer 
(pH 9.6) overnight at 4 oC.  Plates were blocked with Superblock per product 
instructions.  Sera dilutions (100 µL) were made using the blocking buffer and 
allowed to incubate on the plate for 2 h at RT.  The plates were then washed 3 times 
using PBS buffer containing 0.05% Tween 20, and a final time with PBS buffer 
alone.  HRP-conjugated Goat anti-Mouse Monoclonal Antibody (Sigma, St. Louis, 
MO) was diluted 1:500 in blocking buffer, plated (100 µL) and incubated for 1 h at 
RT.  The plates were then washed as above, and 3,3’5,5’-TetraMethylBenzidine 
(TMB) substrate (100 µL) (Sigma, St. Louis, MO) was added.  After 30 minutes at 
RT, 2 M HCl (100 uL) was added to quench the reaction and plates were read using a 
SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA) at 450 nm.   
Tip proteins were plated (100 µL) onto Costar® non-treated black with clear 
bottom plates (Corning Life Sciences, Lowell, MA) at 10 µg/ml in carbonate buffer 
overnight at 4 oC.  Plates were blocked with casein buffer (pH 7.5) for 30 min. 
Subsequent steps were the same as those for the needle ELISA protocol with the 
exception that the casein buffer was used in place of the Superblock.  In all cases, 
endpoint titers were determined as the inverse of the dilution with optical density at 






3.2.4   Statistical Analysis 
The geometric mean was used to represent group responses, and error was 
determined as the standard deviation.  Statistical significance was determined with 
Student’s t-test using Microsoft Excel.  Significance was determined as p ≤ 0.05.  
 
3.3 Results  
 
Mice were intramuscularly immunized three times at two week intervals 
(study days 1, 14 and 28), and blood samples were collected on days 0, 7, 21, 35, and 
49.  For all cases, in which significant increases in IgG were observed, all mice had 
endpoint titers within two dilutions of the geometric mean.  On day 0 of the first 
experiment, all mice had Anti-MxiH IgG titers near 128 (Figure 3.1A).  Mice in the 
control group maintained a similar value throughout the study.  Animals dosed with 1 
µg of MxiH (M1) showed only a slight increase in antibody response throughout the 
study (p<0.02, day 49 compared to day 0), while those administered a 10 µg dose 
(M10) showed some response after the second booster compared to the control groups 
(p<0.0015).  Mice who received the highest dose of 50 µg (M50) displayed an 
increase in serum IgG following the initial dose (p=0.0002), and continued to increase 
following the two booster injections.  Those animals who received bivalent doses of 1 
µg (MD1) did not show a significant increase in Anti-MxiH IgG during the 































































Figure 3.1.  Anti MxiH (A) and IpaD (B) IgG serum responses following 
intramuscular injections on study days 1, 14, 28 of Control (■), M1/D1 (■), M10/D10 











response relative to the control groups was observed after the initial dose and rose 
again following the first and second boosters.  The largest bivalent dose of 50 µg  
(MD50) resulted in a dramatically increased response relative to the lower bivalent 
and all monovalent groups.  In all cases, the responses observed following the second 
booster were sustained for three weeks after the last injection. 
When assayed for Anti-IpaD antibodies at day 0, all mice had endpoint titers 
of approximately 32, and those mice in the control groups continued at a similar low 
level throughout the remainder of the experiment (Figure 3.1B).  Mice which were 
injected with 1 µg of IpaD (D1) showed a slight increase in IpaD IgG following the 
first injection (p<0.05) followed by an increase of greater than 10 dilutions after the 
first booster.  The 10 µg dose (D10) showed a larger increase in antibody titer 
compared to the 1 µg dose following the initial injection, and a similar increase 
following the first booster.  The 50 µg dose (D50) followed the same trend with 
higher endpoints following the first two doses relative to the two lower dose groups.  
IgG titers for IpaD when administered in the presence of MxiH (MD 1, 10, 50) are 
analogous to those observed when IpaD was dosed alone.  The only significant 
difference occurs following the initial injection, where the bivalent dosed mice have 
higher IgG titers than those who received IpaD alone.  As seen with the MxiH IgG 
responses, those observed for IpaD following the second booster remained at a 
comparable level for all groups when sampled on study day 49. 
The second and third studies followed the same immunization and blood 
collection schedule as the initial experiment.  In the second study, all monovalent 
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doses were 10 µg while those containing both antigens had 10 µg of each included.  
Similar to the initial experiment, all mice had Anti-MxiH IgG endpoint titers of 
approximately 256 on day 0, and the control group maintained similar values 
throughout the study (Figure 3.2A).  Those animals who received a 10 µg dose of 
MxiH in formulation buffer (M-Soln) did not show a significant response throughout 
the entire study.  When the same dose was administered adsorbed to Alhydrogel (M-
Al), again no response was observed.  In the presence of IpaD, however, an increase 
in Anti-MxiH IgG was observed following the second booster (p<0.0001).  A 
significant Anti-MxiH IgG response was observed following the initial injection and 
further increased following the first booster when mice were inoculated with the 
polymerized form of MxiH in solution (N-Soln.).  The responses observed following 
the second booster increased only slightly (p<0.05).  When the same dose was 
administered adsorbed to the adjuvant (N-Al), a similar trend was observed with 
increased magnitude.  In the presence of IpaD, the response was identical to that in its 
absence with the exception of the response following the initial injection which was 
slightly higher in the presence of IpaD. 
The anti-IpaD endpoint dilution for all mice prior to the first injection of study 
2 as well as mice in the control group throughout was 32 (Figure 3.2B).  Mice 
inoculated with a 10 µg dose of IpaD in solution (D-Soln) displayed a significant 
response following the first and second injections and maintained the IgG titer 
thereafter.  When adsorbed to Alhydrogel (D-Al), the same response trend was 


























































Figure 3.2.  Anti MxiH (A) and IpaD (B) IgG serum responses following 
intramuscular injections on study days 1, 14, 28 Control (■), M-Soln/D-Soln (■), M-












MxiH (MD-Al), the initial dose elicited a slightly lower response than that of 
adsorbed IpaD alone (p<0.01), and the bivalent formulation did not reach the same 
endpoint titer following the boost injections.  Mice given the bivalent formulation 
containing the polymerized MxiH displayed an identical profile to that of D-Al with 
the exception of the final time-point where the response was slightly lower (p<0.01).      
The final study involved analogous needle and tip proteins from Salmonella 
spp.  At the study start, all mice displayed PrgI specific IgG endpoint titers of 
approximately 64 (Figure 3.3A).  The control group displayed a similar value 
throughout the study.  Mice given the 1 µg dose of PrgI (P1) demonstrated an 
increase in titer over the course of the experiment (p<0.005, day 49 compared to day 
0).  The mice inoculated with 10 µg (P10) displayed an increase following the first 
dose, and levels rose somewhat during the remainder of the experiment.  The mice in 
the highest Alhydrogel adsorbed dose group (P50), had increasing titers following 
each injection, while in the absence of Alhydrogel (P50-Soln), the response was 
comparable to that of P1 and P10.  When dosed in the presence of SipD, the response 
to 1 µg (PS1) is slightly higher at day 21 (p<0.05), but similar thereafter to P1.  At 10 
µg (PS10), the PrgI IgG endpoints mirrored that of the antigen in the absence of 
SipD.  At the highest dose level (PS50), the response followed a similar trend to that 
of the P50 treated mice, although the level was not as great following the second 
boost injection.  The bivalent 50 µg solution dose (PS50-Soln) had similar values to 
that of the monovalent solution dose (P50-Soln) with the exception of day 7 where 






























































Figure 3.3:  Anti PrgI (A) and SipD (B) IgG serum responses following 
intramuscular injections on study days 1, 14, 28 of Control (■), P1/S1 (■), P10/S10 
(■), P50/S50 (■), P50-Soln/S50-Soln (■), PS1 (□), PS10 (□), PS50 (□) and PS50-












The endpoint titers in the SipD groups of Study 3 were roughly 16 prior to 
injections (Figure 3.3B).  Mice given 1 µg doses of SipD (S1) demonstrated a slightly 
elevated endpoint after the first injection, but experienced a boost of more than 5 
dilutions following the second dose.  Mice in the 10 µg dose (S10) group followed a 
similar trend with increased endpoint titers at each time-point.  The 50 µg (S50) dose 
did not elicit a significant difference in antibody response compared to that of S10 
treated mice with the exception of day 7 where S50 was greater (p<0.01).  When no 
Alhydrogel was present (S50-Soln), the response to the initial injection was 
comparable to that observed for S10 and S50.  Following the booster doses, however, 
the increase in antibody levels was not as great.  The 1 µg bivalent formulation (PS1) 
followed the trend observed for the monovalent (S1) formulation, but with lower 
antibody values.  The 10 and 50 µg combination doses (PS10 and PS50) also behaved 
similarly to their monovalent analogues, S10 and S50, but with lower titers at all 
time-points.  When the bivalent formulation was injected in the absence of 
Alhydrogel (PS50-Soln), the observed response was lower than that of the S50-Soln 




In the present study, the immunogenicity of TTSS needle and tip proteins both 
in monovalent and bivalent formulations has been demonstrated.  Additionally, no 
adverse effects were observed throughout the dosing regimen as indicated by normal 
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weight gain patterns (data not shown).  In all studies where increases in specific 
antibody titers were observed, there were no non-responders suggesting that the 
formulations may be efficacious if IgG levels are predictive of protection. 
MxiH monomer has shown to be weakly immunogenic and dose dependent, 
requiring fairly high doses of antigen, multiple boosts and the presence of an adjuvant 
to elicit a strong response.  When administered in the presence of IpaD, however, the 
Anti-MxiH specific IgG was significantly boosted.  This enhanced response does not 
appear to be the result of physical interaction between the two proteins when 
combined in solution (data not shown.) It is possible however that the presence of 
Alhydrogel provides a platform for interaction between the two.  It is also possible 
that IpaD has inherent adjuvant-like properties as evidenced by its sizeable 
immunogenicity when dosed alone in the absence of an adjuvant. 
The polymerized form of the needle protein, expressed without the C-terminal 
truncation, is drastically more immunogenic than the monomeric version.  There 
exists a well established correlation between antigen size and immune response 15.  
Thus, it is possible that the increase observed here is a result of the increased size of 
the polymeric version of the needle monomer.  Another possibility is the existence of 
repeating epitopes in the polymeric unit which has also been shown to greatly 
increase immunogenicity.  Finally, it is also possible that the 5 residue C-terminal 
region which is absent in the monomeric form constitutes a potent epitope.  Similar to 
the monomeric version, the response of the polymerized form is further boosted by 
adsorption to an adjuvant. 
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The tip protein from the Shigella system is shown here to be highly 
immunogenic in agreement with previous work 20.  In contrast to the needle monomer 
MxiH, IpaD does not show significant dose-dependent behavior when administered in 
a multi-dose regimen; however there does appear to be an indication of dose-
dependency following the first inoculation.  As stated above, it is possible that due to 
its potent immunogenicity, IpaD may act as an adjuvant in multivalent formulations.  
While IpaD is strongly immunogenic alone, it does benefit from adsorption to 
Alhydrogel.  
Antigens from the Salmonella system also appear to elicit substantial immune 
responses.  Similar to the results observed for the Shigella system, the monomeric 
needle protein PrgI is less immunogenic than the tip protein SipD.  PrgI displays dose 
dependent behavior, and titers increase markedly when booster doses are 
administered.  As one would expect, IgG responses to PrgI are enhanced when the 
antigen is adsorbed to Alhydrogel.  Contrary to the immune response to MxiH seen in 
the presence of the analogous tip protein, however; PrgI does not produce higher 
antibody levels in the presence of SipD.   
Mice injected with SipD had high antibody titers following the first dose and 
were relatively dose independent after the first booster injection.  This trend is similar 
to that observed for IpaD, but in all cases, responses to SipD were lower in 
magnitude.  Additionally, where IpaD was boosted slightly by the presence of MxiH, 
SipD titers appear to be reduced when administered in the presence of PrgI.  This 
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observation agrees with the documented immuno-suppressing activity associated with 
LcrV, the tip protein of Yersinia pestis 24. 
While the studies presented here support further vaccine development 
utilizing TTSS needle and tip proteins, further work is clearly necessary.  Additional 
studies will focus on tailoring the formulation to elicit an appropriate response based 
on the pathogenesis of each species to ensure protection.  Salmonella spp. bacterial 
infections often result in systemic invasion, which are responsible for some of the 
most severe symptoms 3.  Preventing a systemic infection may be possible using 
versions of the formulation studied here which was dosed intramuscularly.  While no 
data is currently available to definitively associate the presence of PrgI/SipD specific 
IgG with protection, needle proteins have been shown to enhance well-established 
opsinization phenomenon and in-vitro studies suggest that tip protein antibodies 
prevent host-cell invasion 12.  
In contrast, Shigella infections generally involve the epithelial cells of the 
intestines and do not commonly result in septicemia.  This suggests that a vaccine 
will need to protect the mucosal surfaces to be effective.  It is not yet certain whether 
the current formulation will meet this requirement.  To explore this question, it will 
be necessary to conduct additional immunogenicity experiments focusing on IgA 
levels.  Other tests which may be necessary include evaluation of cellular responses 
and associated adjuvants and the effect of the route of administration.  In this study, 
an aluminum salt adjuvant was chosen because it is currently the only FDA approved 
 93
vaccine adjuvant.  Novel adjuvants are now becoming available, however, and they 
will need to be examined in this system 33-36.   
As previously stated, the main purpose of the work presented here is to 
establish the antigenic potential of TTSS needle and tip proteins.    This chapter 
shows that administration of these proteins results in robust humoral immune 
responses.  Based on previous work, this may be sufficient for protection.  While 
some bivalent formulations did not have a synergistic effect, it is proposed that the 
multivalent approach may be advantageous for several reasons including increased 
likelihood of protection across populations and potential cross-protection among 
similar species.  In summary, this chapter supports the development of TTSS proteins 






1. 2005. World Health Organiation Drug-Resistant Salmonella., ed. 
2. 2009. Shigella. ed. 
3. S.M. G 2002. Salmonellosis in children in developing and developed 
countries and populations. Curr Opin Infect Dis  15(5):507-512. 
4. 2008. Salmonella Saintpaul Outbreak. ed. 
5. 2008. Peanut Product Recalls:  Salmonella Typhimurium. ed. 
6. Brooks JT, Shapiro RL, Kumar L, Wells JG, Phillips-Howard PA, Shi Y-P, 
Vulule JM, Hoekstra RM, Mintz E, Slutsker L 2003. Epidemiology of Sporadic 
Bloody Diarrhea in Rural Western Kenya. Am J Trop Med Hyg  68(6):671-677. 
7. Fulla N, Prado V, Duran C, Lagos R, Levine M 2005. Surveillance for 
Antimicrobial Resistance Profiles Among Shigella Species Isolated from a Semirural 
Community in the Northern Administrative Area of Santiago, Chile. Am J Trop Med 
Hyg  72(6):851-854. 
 94
8. Kariaki S, Gilks C, Corkill J, Kimari J, Benea A, Waiyaki P, Hart CA 1996. 
Multi-drug resistant non-typhi salmonellae in Kenya. J Antimicrob Chemother  
38(3):425-434. 
9. Glynn MK, Bopp C, Dewitt W, Dabney P, Mokhtar M, Angulo FJ 1998. 
Emergence of Multidrug-Resistant Salmonella enterica SerotypeTyphimurium DT104 
Infections in the United States. N Engl J Med  338(19):1333-1339. 
10. Deane JE, Roversi P, Cordes FS, Johnson S, Kenjale R, Daniell S, Booy F, 
Picking WD, Picking WL, Blocker AJ, Lea SM 2006. Molecular model of a type III 
secretion system needle: Implications for host-cell sensing. Proc Natl Acad Sci USA  
103(33):12529-12533. 
11. Kubori T, Matsushima Y, Nakamura D, Uralil J, Lara-Tejero M, Sukhan A, 
Gal, aacute, n JE, Aizawa S-I 1998. Supramolecular Structure of the Salmonella 
typhimurium Type III Protein Secretion System. Science  280(5363):602-605. 
12. Espina M, Olive AJ, Kenjale R, Moore DS, Ausar SF, Kaminski RW, Oaks 
EV, Middaugh CR, Picking WD, Picking WL 2006. IpaD Localizes to the Tip of the 
Type III Secretion System Needle of Shigella flexneri. Infect Immun  74(8):4391-
4400. 
13. Espina M, Ausar SF, Middaugh CR, Picking WD, Picking WL 2006. 
Spectroscopic and Calorimetric Analyses of Invasion Plasmid Antigen D (IpaD) from 
<i>Shigella flexneri</i> Reveal the Presence of Two Structural Domains. 
Biochemistry  45(30):9219-9227. 
14. Johnson S, Roversi P, Espina M, Olive A, Deane JE, Birket S, Field T, 
Picking WD, Blocker AJ, Galyov EE, Picking WL, Lea SM 2006. Self-chaperoning 
of the type III secretion system needle tip proteins IpaD and BipD. J Biol 
Chem:M607945200. 
15. Dintzis RZ, Okajima M, Middleton MH, Greene G, Dintzis HM 1989. The 
immunogenicity of soluble haptenated polymers is determined by molecular mass and 
hapten valence. J Immunol  143(4):1239-1244. 
16. Guzman CA, Borsutzky S, Griot-Wenk M, Metcalfe IC, Pearman J, Collioud 
A, Favre D, Dietrich G 2006. Vaccines against typhoid fever. Vaccine  24(18):3804-
3811. 
17. Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB 2007. Clinical 
trials of Shigella vaccines: two steps forward and one step back on a long, hard road. 
Nat Rev Micro  5(7):540-553. 
18. Boyle EC, Bishop JL, Grassl GA, Finlay BB 2007. Salmonella: from 
Pathogenesis to Therapeutics. J Bacteriol  189(5):1489-1495. 
19. Plotkin SA, Orenstein WA. 2004. Typhoid Fever Vaccines. In Levine MM, 
editor Vaccines, 4 ed., Philadelphia: Elsevier, Inc. p 1057-1093. 
20. Turbyfill KR, Mertz JA, Mallett CP, Oaks EV 1998. Identification of Epitope 
and Surface-Exposed Domains of Shigella flexneri Invasion Plasmid Antigen D 
(IpaD). Infect Immun  66(5):1999-2006. 
21. Hill J, Leary SE, Griffin KF, Williamson ED, Titball RW 1997. Regions of 
Yersinia pestis V antigen that contribute to protection against plague identified by 
passive and active immunization. Infect Immun  65(11):4476-4482. 
 95
22. Williamson ED, Eley SM, Stagg AJ, Green M, Russell P, Titball RW 2000. A 
single dose sub-unit vaccine protects against pneumonic plague. Vaccine  19(4-
5):566-571. 
23. Williamson ED, Vesey PM, Gillhespy KJ, Eley SM, Green M, Titball RW 
1999. An IgG1 titre to the F1 and V antigens correlates with protection against plague 
in the mouse model. Clin Exp Immunol  116(1):107 - 114. 
24. Brubaker RR 2003. Interleukin-10 and Inhibition of Innate Immunity to 
Yersiniae: Roles of Yops and LcrV (V Antigen). Infect Immun  71(7):3673-3681. 
25. Kingston R, Burke F, Robinson JH, Bedford PA, Jones SM, Knight SC, 
Williamson ED 2007. The fraction 1 and V protein antigens of Yersinia pestis 
activate dendritic cells to induce primary T cell responses. Clinical and Experimental 
Immunology  149(3):561-569. 
26. Matson J, Durick K, Bradley D, Nilles M 2005. Immunization of mice with 
YscF provides protection from Yersinia pestis infections. BMC Microbiology  
5(1):38. 
27. Swietnicki W, Powell BS, Goodin J 2005. Yersinia pestis Yop secretion 
protein F: Purification, characterization, and protective efficacy against bubonic 
plague. Protein Expression and Purification  42(1):166-172. 
28. Darboe N, Kenjale R, Picking WL, Picking WD, Middaugh CR 2005. 
Physical characterization of MxiH and PrgI, the needle component of the type III 
secretion apparatus from Shigella and Salmonella. Protein Sci  15(3):543-552. 
29. Espina M, Ausar SF, Middaugh CR, Baxter MA, Picking WD, Picking WL 
2007. Conformational stability and differential structural analysis of LcrV, PcrV, 
BipD, and SipD from type III secretion systems. Protein Sci  16(4):704-714. 
30. Kenjale R, Wilson J, Zenk SF, Saurya S, Picking WL, Picking WD, Blocker 
A 2005. The Needle Component of the Type III Secreton of Shigella Regulates the 
Activity of the Secretion Apparatus. J Biol Chem  280(52):42929-42937. 
31. Marquart ME, Picking WL, Picking WD 1995. Structural Analysis of 
Invasion Plasmid Antigen D (Ipad) from Shigella flexneri. Biochemical and 
Biophysical Research Communications  214(3):963-970. 
32. Golde WT, Gollobin P, Rodriguez LL 2005. A rapid, simple, and humane 
method for submandibular bleeding of mice using a lancet. Lab Anim (NY)  
34(9):39-43. 
33. Aguilar JC, Rodríguez EG 2007. Vaccine adjuvants revisited. Vaccine  
25(19):3752-3762. 
34. Ott G, Radhakrishnan R, Fang JH, Hora M. 2001. The adjuvant MF59: a ten 
year perspective Vaccine Adjuvants: Preparation Methods and Research Protocols, 
ed., Totowa, N.J.: Humana Press. p 211-228. 
35. Skene CD, Sutton P 2006. Saponin-adjuvanted particulate vaccines for 
clinical use. Methods  40(1):53-59. 
36. Wikman M, Friedman M, Pinitkiatisakul S, Andersson C, LÃ¶vgren-
Bengtsson K, LundÃ©n A, StÃ¥hl S 2006. Achieving directed immunostimulating 
























4.1   Introduction 
 
Despite modern advances, gram-negative bacterial pathogens continue to 
persist as serious health risks for humans, particularly in the developing world.  These 
agents cause diseases such as bacillary dysentery (Shigella flexneri), septicemia 
(Salmonella typhi, Burkholderia pseudomallei and Yersinia pestis), gastroenteritis 
(Salmonella typhimurium, Yersinia enterocolitica) and chronic infections in 
compromised individuals (Pseudomonas aeruginosa).  Shigella alone is estimated to 
cause 165 million infections each year worldwide with over a million deaths.1  The 
severity and frequency of such infections highlights the need for safe, efficacious 
vaccines that can be inexpensively produced and administered anywhere in the world.  
This need has increased in the last 20 years with the emergence of antibiotic resistant 
strains for many of the pathogens mentioned above.2-5   
Proteins from the type III section system (TTSS) of important pathogens have 
been selected for the development of targeted subunit vaccines.  The TTSS plays an 
integral role in the pathogenesis of these bacteria either by facilitating host cell 
invasion or by preventing macrophage phagocytosis.6,7   The type III secretion 
apparatus (TTSA) is comprised of a basal body and needle, which together span the 
inner and outer bacterial membrane and extend into the extracellular space.6-8  The 
overall complex is composed of more than 20 proteins and functions to translocate 
effector proteins from the bacterial cytoplasm into the membrane and cytoplasm of a 
host cell.   
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A specific class of protein has recently been shown to localize to the 
extracellular end of the TTSA needle where it functions to regulate the secretion of 
other proteins passing through the TTSA.9-12  Due to the location and function of 
these so called tip proteins, it is anticipated that they would be effective antigens in a 
sub-unit vaccine.  The five tip proteins selected for this vaccine formulation study are 
IpaD from S. flexneri, BipD of B. pseudomallei, SipD of Salmonella spp., LcrV of 
Yersinia spp. and PcrV of P. aeruginosa.  These proteins, ranging in size from 32 to 
37 kDa, possess primarily α-helical secondary structure and are dumbbell shaped with 
a central coiled coil separating the N and C terminal domains.10,13-17  It has previously 
been established that, in animal models, these prospective antigens are highly 
immunogenic and provide at least a degree of protection.18-21  Furthermore, in the 
case of Shigella, experiments have demonstrated that in vitro, anti-IpaD IgG 
neutralized host cell invasion in model systems.9 
While the tip proteins show promise in eliciting an appropriate, protective 
immune response, it is important that any formulation involving these antigens be 
sufficiently stable to permit distribution to regions of the world lacking reliable 
refrigerated storage.22  This requirement demands any such product possess greater 
stability than is often expected for marketing in developed countries.   Until now, 
little attention has been given to formulation considerations for these tip proteins.  
This chapter describes studies to systematically ascertain optimal formulation 
compositions and conditions.  This has been done with the ultimate goal of combining 
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these antigens into a single multivalent vaccine.  As such, a single formulation is 
sought which stabilizes all of the antigens.   
An adjuvant is often necessary for subunit vaccines to increase the immune 
response.23  This boost in immunogenicity is accomplished by a variety of 
mechanisms ranging from activation of Toll-like receptors on antigen presenting cells 
to creating an antigen depot.23-25  The adjuvant selected for this project is the 
aluminum salt Alhydrogel®.  The mechanism of action of this crystalline substance 
has not been fully elucidated.26-30 Nevertheless, due to its excellent safety record, 
inclusion in many FDA approved commercial vaccines and the pI’s of the tip protein 
(all between ~5 and 5.5 which facilitates electrostatic interactions with the positively 
charged adjuvant) it is the obvious choice.30-33  Adsorption and desorption studies 
were conducted to elucidate the nature of protein-Alhydrogel® interactions. 
  
4.2   Materials and Methods 
4.2.1   Materials    
Recombinant proteins were expressed and purified as described 
previously.15,34,35  All proteins were dialyzed into 20 mM citrate/phosphate buffer at 
pH 7 and stored at -80 C°.    For the final formulation, a 10 mM histidine buffer was 
selected containing 5 mM phosphate.  Phosphate was included to exchange some of 
the exposed aluminum hydroxide to aluminum phosphate, thus lowering the pH 
microenvironment at the adjuvant/protein interface.  All buffer components were 
purchased from Sigma-Aldrich (St. Louis, Mo). 
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4.2.2   Excipient Screening    
A high throughput screening method was devised to identify additives that 
could serve as stabilizers in a pharmaceutical formulation.  Previous work indicted 
that all of the putative antigens aggregated significantly at pH 5 and 6 at elevated 
temperatures. This physical degradation pathway was selected because it could be 
easily adapted for high throughput screening.17  An assay was developed employing 
96 well plates at 55 °C using a SpectraMax plate reader (Molecular Devices, 
Sunnyvale, CA) measuring time-dependent optical density at 360 nm. Samples were 
analyzed in duplicate with a negative control containing buffer and excipient on the 
same 96 plate.  Measurements were taken at 2 min intervals for a period of 2 h.  The 
effectiveness of each additive was quantified by percent inhibition of aggregation.  


















where ΔOD360 (E) change in optical density over the course of the experiment of the 
protein with excipient present and ΔOD360 (A) represents the same measurement 
without excipient. 
To create the appropriate sample conditions, protein stock solutions were 
diluted to 0.2 mg/ml in 20 mM citrate phosphate buffer at pH 5.  All excipients tested 
belong to the GRAS (generally regarded as safe) library of compounds which 
includes a selection of amino acids, antioxidants, cyclodextrans, surfactants, 
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carbohydrates, polyols and proteins among other agents (see results section).  These 
GRAS additives have proven track-records in pharmaceutical formulations. 
 
4.2.3   Intrinsic Trp Fluorescence  
The environment of Trp residues was monitored using fluorescence to 
measuring tertiary structural stability in the presence and absence of promising 
stabilizers.  Samples, excited at 295 nm, had emission monitored from 300 to 400 nm 
using a 0.5 s integration time and a resolution of 1 nm.  Emission was measured 90° 
from the direction of the incident beam with a PTI QM-1 spectrofluorometer with a 
four position rotating turret (Brunswick, NJ).    Quartz cuvettes with a 1 cm 
pathlength were used and were filled to a volume of 1 ml.  In the case of samples 
containing Alhydrogel®, front face fluorescence was employed after permitting 
samples to settle overnight.29  Samples were measured from 10 to 85 °C in 2.5 °C 
increments where temperature was controlled using a water bath cooled peltier 
system.   Peak positions were determined using Origin® software by fitting the data 
to a 2° polynomial followed by first derivative analysis.  Where possible, a sigmoidal 
function was fit to the data to estimate Tm values.   
In addition to thermal stress studies, long term stability of the final 
formulations was also monitored by Trp fluorescence using the instrument settings 
described above.  Temperature conditions equivalent to the long term stability storage 
temperature were used for measurements.  Disposable Brand UV semi-micro cuvettes 
(1-3 mL) purchased from Sigma were using for these studies. 
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4.2.4   Adjuvant Binding Studies  
The aluminum hydroxide product Alhydrogel® was selected due to its zero 
point charge (approximately 11) which suggests it could potentially form desirable 
ionic interactions with the tip proteins.  For binding assays, Alhydrogel® was diluted 
to 0.5 mg/ml while the protein concentration was varied from approximated 0.1 mg to 
0.7 mg in a solution totaling 1 ml.  A 10 mM Histidine/5 mM phosphate buffer was 
selected since this buffer was the initial choice for final formulation based on earlier 
studies.17  The concentration of the proteins prior to adjuvant addition was confirmed 
with an Agilent 8453 diode array spectrophotometer by measuring ultraviolet (UV) 
absorption spectra from 200-400 nm.  Concentrations were calculated from the 
absorbance at 280 nm.  Adjuvant was added and the samples were tumbled on an end-
over-end tube rotor at 4 °C for 1 h to ensure steady state was reached.  Adjuvant was 
then pelleted by centrifugation at 14,000g for 1 min.  The UV Absorbance of the 
supernatant was recorded to ascertain the concentration of free protein.  From the 
initial and supernatant protein amounts, mass balance calculations gave bound protein 
values.   
Protein desorption from Alhydrogel® was explored using compounds known 
to frequently disrupt specific binding mechanisms. These include sodium chloride 
(2M), sodium phosphate (1M) and sodium citrate (1M).  Samples containing 0.1 mg 
of protein were pelleted as described above and the supernatants were replaced with 
an equal volume of one of the potentially protein-adjuvant disrupting solutions.  After 
reconstitution, samples were tumbled for 1 h and the adjuvant was again centrifuged 
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to pellet the adjuvant.  Concentrations of protein in the supernatant were determined 
as described previously. 
   
4.2.5   Long Term Stability Studies  
Potential formulations were tested for long term stability at 25 °C for each of 
the five sub-unit vaccine candidates.  Formulations consisted of 1 mL samples of 0.1 
mg protein and 0.5 mg Alhydrogel® in solutions containing 10% sucrose and 5% 
dextrose.  Positive controls containing no excipient and negative controls lacking tip 
proteins were included in the study.  Chemical stability was quantified by desorbing 
the proteins from the adjuvant after 40 days at 40 °C with 1 M sodium phosphate.  
Samples were subjected to trypsin digestion (0.05mg/ml trypsin for 8 hrs at 37 °C) 
and subjected to capillary liquid chromatography-mass spectrometry (LC-MS).  The 
capillary liquid chromatography column was directly connected to a LTQ-FT Ultra 
Hybrid Mass Spectrometer (ThermoFinnigan) as described 36.  MS/MS results were 
processed using TurboSequest batch search in BioWorks 3.2 software.  After 
subsequent data analysis with an in house Perl script, the Mascot (v2.2, Matrix 
Science) database-searching program was used to identify the peptides and proteins.  
All major protein degradation pathways were explored during this process.  Results 
were imported into Scaffold 2.2.03 software (Proteome Software Inc.) for viewing 




4.3   Results and Discussion 
4.3.1   Excipient Screening and Optimization in Solution 
To increase the stability of proteins in solution, a variety of compounds and 
polymers are typically included in commercial formulations.  In this case, a library of 
GRAS (generally regarded as safe) compounds was tested for stabilizing effects.  
Components of this library include amino acids, antioxidants, cyclodextrans, 
carbohydrates, surfactants, polyols and proteins (see Table 4.1 for further examples) 
which potentially stabilize through a variety of mechanisms.  Based on previous work 
in Chapter 2, one of the tip proteins’ major degradations pathways at elevated 
temperatures was aggregation. Therefore turbidity was chosen to identify potential 
stabilizers.17  Turbidity was monitored as the optical density at 360 nm as the samples 
were incubated at 55 °C in the presence excipients.   
Results of excipient screening are shown in Table 4.1 where the average 
percent inhibition has been used to rank order the stabilizers.  Only excipients which 
had an average positive percent inhibition are shown.  Individual percent inhibition 
values varied by no more than ± 5% except in cases of greater than 50% negative 
inhibition where error was often as large as the absolute values of the results shown.  
Based on this study, sugars and polyols appear to have the greatest stabilizing effects 
on the proteins with dextrose inhibiting aggregation to the greatest extent.  
Interestingly, the ability of dextrose to stabilize is effectively invariant to its 
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Excipients Concentration IpaD  BipD SipD LcrV PcrV Average
Dextrose  20.00% 79 45 69 86 95 75
Sucrose 20.00% 83 44 53 84 89 71
Dextrose  10.00% 74 51 65 70 73 67
Sorbitol 20.00%   35 63 73 92 66
Lactose 20.00% 66 33 76 61 91 65
Glycerol 20.00% 76 39 38 58 87 60
2-OH propyl 
γ-CD 10.00% 21 60 56 64 49 50
Mannitol 10.00% 56 19 49 53 69 49
Sucrose 10.00% 55 35 38 39 67 47
Lactose 10.00% 47 24 53 52 57 47
Trehalose 10.00% 54 0 53 58 61 45
Trehalose 20.00% 79 64 -114 92 78 40
Glycerol 10.00% 47 9 16 39 57 34
Arginine 0.3 M 64 38 11 28 22 33
2-OH propyl 
β-CD 10.00% -52 5 32 66 46 19
Sodium 
Citrate 0.1 M 48 15 12 45 -23 19
α 
Cyclodextrin 2.50% 25 -67 -1 92 32 16
Sorbitol 10.00% 62 -2 -97 35 77 15
Guanidine 0.3 M 53 60 -16 37 -74 12
Pluronic F-
68 0.01% -4 -26 95 -8 -11 9
Sodium 
Citrate 0.2 M 69 56 26 45 -177 4
2-OH propyl 
γ-CD 5.00% -27 37 12 47 -66 1
  
Table 4.1.  Percent Inhibition of Aggregation.  High throughput excipient screening 
expressed in terms of Percent Inhibition of aggregation.  Samples were incubated for 
a period of 2 h at 55 °C at pH 5. Uncertainties are approximately 5 % with the 
exception of the highly negative numbers where error may equal the absolute value of 







concentration (compare 20% to 10% w/v) for IpaD, BipD and SipD.  Many of the 
compounds screened stabilized one or two of the proteins while behaving like 
chaotropic agents with others.  This trend did not follow protein sub-family 
classifications.  Prior biophysical characterization and primary sequence information 
suggested that IpaD, BipD and SipD were more homologous, forming one sub-family 
while LcrV and PcrV belonged in another.17  The additives which most stabilized the 
tip proteins presumably do so through the well known mechanism of preferential 
exclusion.37-40  Preferential exclusion occurs when the compounds are excluded from 
the protein surface which ultimately favors a smaller surface area and therefore 
increases the free energy of unfolding.38-40   
After some additional screening of the best stabilizers from Table 4.1, a 
formulation containing 10% sucrose and 5% dextrose was identified as most potent in 
inhibiting aggregation.  To determine whether the stabilizing mechanism of the 
formulation was due to increased conformational stability or to an excipient/protein 
interaction that directly blocked protein association, tertiary structural stability was 
measured by intrinsic Trp fluorescence.  Fluorescence emission peak position was 
monitored as a function of temperature from 10 to 85 °C at pH 5 (not illustrated) and 
subsequently at pH 7 (Figure 4.1).  In agreement with previous results, IpaD and 
SipD (Figure 4.1A,C) display biphasic transitions indicative of two independent 
folding domains.15-17  The calculated transition midpoint (Tm) for the first transition is 
increased by more than 2 °C for both proteins in the sucrose/dextrose formulation. 
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Figure 4.1:  Intrinsic Trp fluorescence peak position measured from 10 to 85 °C for 
IpaD (A), BipD (B), SipD (C), LcrV (D) and PcrV (E).  The excitation wavelength 
was 295 nm.  The proteins were monitored in the absence ( ) and presence ( ) of 
sucrose 10% and dextrose 5%. Error bars are the standard deviation from at least 








BipD, the other member of the subfamily, appears to have less labile tertiary structure 
with a Tm occurring without excipients at nearly 80 °C and rising above 82 °C in their 
presence.  Transition midpoints for BipD were calculated based on the assumption 
that the curves are beginning to curve towards upper asymptotes.  Estimates of the 
onset of temperature transition (T0) resulted in similar conclusions. 
Unlike the other tip proteins, transitions for LcrV in the presence and absence 
of excipient shift to shorter wavelengths indicating that the Trp residue is moving into 
a more apolar environment.  Transition onsets for LcrV increase by nearly 5 °C in the 
formulation.  Unlike LcrV which exhibited blue shifts in agreement with previous 
work, PcrV shifts to longer wavelengths in this study.  This possibly occurs due to the 
change in buffer system from 20 mM citrate/phosphate to 10 mM histidine/5 mM 
phosphate.  Interestingly, initial emission wavelengths (10°C) and static light 
scattering transitions are similar in either buffer system (not illustrated), suggesting 
that interactions with either the citrate or histidine effect PcrV unfolding, but perhaps 
not its initial conformation nor its propensity to aggregate.  PcrV’s Tm is increased by 
more than 2 °C in the presence of the excipients. 
   
4.3.2   Adjuvant Binding 
To quantify the extent of tip protein adsorption to Alhydrogel®, adsorption 
isotherms were created by incubating known concentrations of the proteins with 
adjuvant at 4 ° C and measuring the unbound protein in the supernatant after 
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centrifugation (Figure 4.2).  Simple mass balance calculations were then used to 
produce the plots shown here.  Conditions were sought under which the antigens are 
at least 95% adsorbed based on the idea that an enhanced immune response is 
dependent on a high degree of antigen adorption.23  In a 1 ml solution containing 0.5 
mg aluminum hydroxide, up to 0.65 mg of IpaD are bound (Figure 4.2A).  LcrV has 
comparable adsorption properties to IpaD and is highly bound throughout the 
experimental range.  BipD and PcrV show less affinity to aluminum hydroxide and 
have similar binding curves to each other.  SipD adsorbs the least, falling below 95% 
adsorption at 0.15 mg.   
It is possible that there is some difference in the mechanism of adsorption for 
BipD, SipD and PcrV compared to LcrV and IpaD.  The most direct evidence for this, 
besides the differences in the adsorption isotherms discussed above, is the adsorption 
properties of the proteins in the presence of the excipients (10% sucrose and 5% 
dextrose).  In studies conducted for the proteins at 0.4 mg (except SipD which 
because of its low binding was tested at 0.15 mg), the highly adsorbed IpaD and LcrV 
have unchanged properties, however, the remaining three proteins show a reduction 
in binding (Figure 4.3).  Upon addition of the formulation stabilizers, the amount of 
protein adsorbed for BipD and SipD is reduced by more than 30% and PcrV 
adsorption is reduced approximately 10%.  Even when the amount of protein added is 
significantly reduced (halved for BipD and PcrV), the percentage of protein adsorbed 
in the presence of the excipients does not reach the levels of protein and adjuvant  
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Figure 4.2:  Adsorption isotherms of IpaD (A), BipD (B), SipD, (C), LcrV (D) and 
PcrV (E) to Alhydrogel® at 4 °C.  The aluminum amount was 0.5 mg in all cases.  































BipD PcrV SipD  
 
Figure 4.3:  Percent of protein adsorbed to 0.5 mg Alhydrogel® in absence ( ) and 
presence ( ) of 10% sucrose 5% dextrose.  Protein content is 0.4 mg for ( , ) and 
0.2 mg for the crosshatched bar with the exception of SipD where the amounts are 







alone.  This phenomenon was observed regardless of the order of addition of the 
components.   
The cause of the reduced adsorption is not completely clear since desorption 
studies of the individual tip proteins give different results (not illustrated).  Three 
different compounds were evaluated (sodium chloride, sodium phosphate and sodium 
citrate) based on their ability to disrupt the protein-aluminum hydroxide interaction.  
Addition of 2 M sodium chloride did not desorb more than 11 % of any of the 
proteins (the highest was SipD), suggesting that the interaction between the antigens 
and the Alhydrogel® is not primarily ionic.  Addition of 1 M sodium phosphate, 
which exchanges hydroxide ions with phosphate, released at least half of IpaD, BipD 
and LcrV but had less effect on SipD and PcrV.  Finally, citrate which partially 
dissolves aluminum hydroxide had results nearly identical to those seen for phosphate 
addition for all of the proteins.  Based on these results it appears that the interaction 
between the proteins and the adjuvant is perhaps a mixture of hydrogen bonding and 
Van der Waals forces, although the relative importance of each may vary by protein.  
While the results from Figure 4.3 would suggest that BipD, SipD and PcrV have 
similar adsorption mechanisms, the other additive studies suggest that BipD is more 
similar to IpaD and LcrV.  The results for BipD may highlight the difference in its 
structure compared to the other proteins.  While the other four tip proteins are 
dumbbell shaped with a coiled-coil in the middle, BipD possess a triple coiled-coil 
which may effect its interaction with the adjuvant .10,14 
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Intrinsic Trp fluorescence data suggest that the chosen excipient combination 
increased protein tertiary structural stability in solution, however, it is important to 
also monitor Trp fluorescence when the antigens are adsorbed to Alhydrogel®.  
Samples were therefore thermally stressed from 10 to 85 °C when bound to the 
adjuvant using front surface Trp fluorescence to minimize light scattering problems 
and Tm values were calculated (Table 4.2).  When comparing the adsorbed proteins to 
those in solution, nearly all samples manifested lower Tm values upon adsorption with 
the exception of IpaD.  The decreased transition temperatures are indicative of 
destabilization of the proteins’ tertiary structures when adsorbed to aluminum 
hydroxide.  IpaD displays a biphasic transition in solution. Its first Tm is displayed in 
Table 4.2, however, only a single transition is observed upon adsorption to the 
adjuvant.  Since the second thermal transition is higher than the Tm in the presence of 
Alhydrogel® it may also be that IpaD is less stable on the adjuvant surface.  
Statistically significant increases in stability are observed when the optimized 
excipient combination is introduced to the adjuvant system, again with the exception 
of IpaD where no change occurs.  Since the concentration of protein in these studies 
is 0.1 mg/ml with over 95% of the protein adsorbed, this suggests that the 
stabilization effect does not reflect the behavior of the free antigen.  While little is 
known about how excipients effect the stability of adsorbed proteins, it seems likely 
that preferential exclusion continues to play a role.37,39,40   It is unclear why IpaD does 
not exhibit increased stability in the presence of sucrose and dextrose in this case.  










 60.4 ± 0.5 64.4 ± 1.4 64.0 ± 4.8 
BipD 
 79.7 ± 0.2 73.7 ± 0.8 78.1 ± 0.3 
SipD 
 56.6 ± 0.4 48.1 ± 0.6 59.6 ± 0.6 
LcrV 
 72.0 ± 0.3 66.7 ± 0.2 70.5 ± 1.1 
PcrV 
 57.2 ± 1.7 54.3 ± 1.0 57.2 ± 1.7  
 
Table 4.2:  Transition midpoints calculated from intrinsic Trp fluorescence 
measurement from 10 to 85 °C.  The solution column provides values for protein 
alone (0.1 mg/ml), the second column shows protein adsorbed to the aluminum 
adjuvant (0.5 mg/ml) and the final column for adsorbed protein in 10% sucrose and 










Therefore, it is possible that there is some change in either the behavior of the 
excipient or the protein upon adsorption.  It is also possible, however, that IpaD is 
sufficiently structurally disrupted in the presence of Alhydrogel® that preferential 
hydration simply has no stabilizing effect. 
 
4.3.3   Long Term Stability 
While thermally stressing the prospective vaccines from 10 to 85 °C is useful 
in predicting stability, it is important to confirm those results with long term 
experiments.  Stability studies were conducted to monitor changes in tertiary structure 
of the proteins adsorbed to Alhydrogel® in the presence and absence of the optimized 
excipient combination at 25 °C.  This was accomplished by measuring peak position 
using intrinsic Trp fluorescence at three to four day intervals for a period of 100 days.  
Data indicate that there is no significant change in fluorescence emission peak 
position in the prospective vaccine during this time (data not shown).  Tip proteins 
adsorbed to adjuvant in the absence of the excipients also showed no statistically 
significant variance in fluorescence emission.  These results indicate that either the 
proteins possess physical stability for greater than three months or that intrinsic Trp 
fluorescence is not sensitive to the tertiary structural changes that occur over time.  
UV spectroscopy was used to measure possible desorption of proteins or protein 
fragments.  No such events were observed, suggesting that the physical interactions 
responsible for adsorption are unchanged and possibly enhanced over time. 
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Capillary liquid chromatography and mass spectrometry (LC-MS) analysis 
provided information on possible chemical degradation.  Proteins in the potential final 
formulations as well as proteins adsorbed to adjuvant alone were stored at 40 °C for 
40 days.  The incubated proteins were desorbed from adjuvant using 1 M sodium 
phosphate and then digested using trypsin.  As a negative control, fresh samples were 
also analyzed.  Asn deamidation was the predominant degradation pathway and is 
shown Table 4.3 (in the case of SipD some Gln degradation was also observed).  
Analysis of LcrV samples did not reveal chemical modifications under any 
circumstances.  Primary sequence data for IpaD revealed three Asn residues followed 
by Gly which are especially susceptible to deamidation and consequently even fresh 
samples showed some deamidation of Asn (Table 4.3).41,42  IpaD also experienced 
deamidation in the presence of 10% sucrose and 5% dextrose, but much more 
extensive degradation occurred in their absence.  For SipD Asn88 and PcrV Asn252, 
deamidation events observed with protein and adjuvant alone were undetectable in 
the final formulation.  In the case of BipD, however, the second residue deamidated 
completely under either incubation condition.  Interestingly, a small amount of 
deamidation was observed in the fresh sample at Asn270 but not seen in incubated 
samples.  It is possible that adsorption to the adjuvant alters the secondary or tertiary 
structure such that the Asn270 Φ and Ψ angles no longer permit facile deamidation.  
If one assumes that the secondary and tertiary structure of these proteins is 
stabilized in long term stability conditions in the presence of the optimized excipient 






    IpaD        BipD   
AA # Fresh A +E  AA # Fresh A +E 
48 10 20 9  2 0 100 100 
107 0 3 0  270 2 0 0 
241 0 100 100          
266 65 100 100          
305 7 50 0          
         
    SipD        PcrV   
AA # Fresh A +E  AA # Fresh A +E 
88 1 2 0  252 2 30 0 
  
Table 4.3.  Percent deamidation of tip proteins Asn residues.  Only Asn residues 
which displayed significant degradation are shown.  The initial column for each 
protein lists the primary sequence number.  This is followed by results for fresh 
protein subjected to tryptic digest.  The A and +E columns represent samples 
incubated at 40 °C for 40 days in the absence and presence of excipients respectively.  











chemical degradation results observed for most proteins is not surprising.  There is 
mounting evidence that proteins are in general more chemically stable when a high 
degree of secondary and tertiary structure exists.43-49  Indeed, even the deamidation in 
BipD does not refute this explanation.  Since the Asn residue is second in the primary 
sequence, it is probably not part of any rigid structural feature that would inhibit the 
formation of the critical cyclic-imide intermediate. 
 
4.4   Conclusions 
 
 Subunit vaccines containing multiple antigens offer many advantages 
including increased patient compliance and cost, but finding formulation conditions 
appropriate for all antigens is often difficult.  The purpose of this chapter was to show 
how biophysical methods can be used to methodically expedite formulation even in 
complex systems.  Choosing aggregation as the degradation pathway to monitor, high 
throughput screening of a GRAS library of compounds was accomplished for all five 
TTSA needle tip proteins.  Following additional analysis, an optimized excipient 
combination (10% sucrose and 5% dextrose) was identified.  This excipient 
combination was shown to stabilize the proteins both in solution and when adsorbed 
to Alhydrogel® under thermal stress studies.  Adsorption isotherms and desorption 
experiments were conducted to characterize the nature of the interaction of the 
proteins with aluminum hydroxide.  IpaD and LcrV have the strongest interaction 
with Alhydrogel.  This interaction is not affected by the inclusion of excipients.  Long 
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term stability studies at 25 °C established that the tip proteins’ intrinsic Trp 
fluorescence peak position remains unchanged for over three months.  Initial 
chemical stability data indicate that 10% sucrose and 5% dextrose generally inhibit 
degradation of the proteins.  In the future, additional long term stability and chemical 
stability studies are needed for the five antigens in combination.   
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Biophysical Characterization of Chlamydia trachomatis CT584: 







5.1  Introduction 
 
Chlamydia infections are common throughout the world and cause a range of 
diseases including pneumonia, atherosclerosis, pelvic inflammatory disease, 
reproductive sterility and blindness.1,2  Chlamydia trachomatis alone is responsible 
for an estimated 92 million sexually transmitted infections a year.3  Despite this 
prevalence, much is still unknown about the pathogenesis of these obligate 
intracellular pathogens.  Chlamydia invade eukaryotic cells as a metabolically 
inactive elementary body (EB) and form an inclusion which evades fusion with the 
late endosome/lysosome endocytic vescicles.4-7  In this compartment, EB convert into 
metabolically active reticulate bodies (RB) which replicate by binary fission.4  After 
approximately 18 hrs, RB begin differentiating back into EB and are eventually 
exocytosed to repeat the infection cycle.  The pathogens are also known to exist in a 
persistent form inside host cells presumably to evade immune system responses.2,8,9   
Like many pathogenic Gram-negative bacteria, Chlamydia use type III 
secretion systems (T3SS) to facilitate infection and exploitation of eukaryotic cells.10-
14  In particular, the T3SS of Chlamydia is implicated in host cell invasion, 
intracellular trafficking, and maintenance of the unique intracellular niche of 
Chlamydia.  Early evidence for the T3SS in these bacteria was based primarily on 
genetic information and electron microscopy where protrusions observed on the 
bacterial surface are presumed to be T3SS needles.13-16  The lack of a system for 
genetic exchange in C. trachomatis has hampered functional studies of T3SS 
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components.  Numerous proteins, however, have been demonstrated to be secreted in 
heterologous systems (e.g. Shigella) in a T3SS dependent manner and/or are present 
in the cytosol (or cytosolic face of inclusion) of Chlamydia infected cells, providing 
support for identification of effector molecules and utility of the T3SS in 
Chlamydia.17-23  Unlike most bacteria possessing T3SSs, Chlamydial T3SS genes are 
found at multiple loci throughout the genome which has made identification of 
functional components more difficult.10,24   
T3SS are composed of a basal body and a needle which is responsible for the 
translocation of effector proteins from the bacterial cytosol to the surface of a host 
cell or into its cytoplasm.12,25,26   This secretion apparatus is comprised of more than 
20 distinct proteins and has a possible evolutionary relationship to bacterial flagella.  
One class of protein in this system of particular interest is the tip protein which is so 
named for its propensity to localize to the extracellular needle tip.27-30  These proteins 
have been shown to regulate secretion of the other effector proteins and thus play a 
pivotal role in the pathogenesis of the bacteria.27  Furthermore, T3SS needle tip 
proteins, such as LcrV from Yersinia pestis, have been demonstrated to be excellent 
protective vaccinogens.31-33  In addition, some tip proteins, such as IpaD from 
Shigella flexneri, may have additional roles though these functions are not fully 
understood.  
 In Chapter 2, biophysical tools were employed to understand the 
characteristics of T3SS needle tip proteins from proteobacteria. This work revealed 
protein sub-families based on their response to pH and temperature.34,35  These 
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distinctions were made after creating Empirical phase diagrams (EPDs) which 
provide a global description of results from disparate techniques.36,37  Furthermore, 
the utility of EPDs in highlighting structure/function similarities in proteins with little 
primary sequence homology has been established.38  
The identity of the T3SS needle tip protein is presently unknown for 
Chlamydia.  As presented here, computational structure prediction and homology 
search indicates that a Chlamydia trachomatis ORF (CT584), a protein with no 
primary sequence homology to any other protein with a determined function, exhibits 
predicted structural homology to T3SS needle tip proteins.  In this chapter, we 
hypothesize that CT584 is a functional T3SS needle tip protein.  To test this 
hypothesis, biophysical analyses of CT584 are employed to compare pH/temperature 
responses to the previously analyzed T3SS needle tip proteins.  
 
5.2  Materials and Methods 
5.2.1  CT584 cloning, expression, and purification  
CT584 was PCR amplified from C. trachomatis (L2/434/Bu) using primers 
5’- GGA ATT CCA TAT GAC GAC GAA ACC CAA AAC TC and 5’- CGC CGG 
CCG CCA CAG ATT TCG TTA ATT CTT C (Integrated DNA technologies, 
Coralville, IA). Purified amplicons were restriction enzyme digested (NdeI and EagI) 
and ligated into pET21b (Novagen).  Isogenic transformants were selected and 
propagated in E. coli TOP10 (Invitrogen, Carlsbad, CA). Plasmid constructs were 
confirmed via DNA sequencing (University of Kansas, DNA Sequencing Facility).  
 127
For protein expression, plasmids containing CT584 were freshly transformed into 
BL21(DE3) E. coli (Bioline, Boston, MA) and grown at 37°C in 1 L of Luria-Bertani 
broth with 100 μg/mL ampicillin.  Cells were grown to an OD600 0.7 prior to 1 mM of 
isopropyl-β-D-thiogalactopyranoside being added.  After 4 h of induction, cells were 
centrifuged and pellets frozen.  Thawed cells were resuspended and lysed using 
sonication in a Tris Buffer (40mM Tris, 500mM NaCl, and 5% Glycerol pH 8.0). 
6XHis-tagged CT584 was purified using a cobalt metal affinity resin (Talon beads; 
Pierce) and gravity filtration column.  Protein was eluted in Tris buffer containing 
500mM Imidizole and affinity purified CT584 was applied to a Superdex 200 gel 
filtration column (GE Healthcare) employing an ÄKTA FPLC (GE Healthcare) in 
Tris buffer.  Protein containing fractions were collected at approximately 150 kDa. 
Coomassie stained SDS-PAGE of the protein sample revealed the expected 21 kDa 
monomer at >95% purity. 
  
5.2.2  Ultraviolet Absorption Spectroscopy   
Spectra for each protein were analyzed from 200-400 nm with an Agilent 
8453 diode-array spectrophotometer equipped with a peltier temperature controller.  
The experimental spectral resolution was 1 nm and the integration time was set to 25 
seconds.  Spectra were recorded from 10-90 °C in 2.5 °C increments with a 5 min 
equilibration time at each temperature.  The resultant absorbance data were analyzed 
using Agilent UV-visible ChemStation™ software by fitting spectra to a fifth degree 
Savitzky-Golay polynomial followed by a second derivative calculation.  The 
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derivative spectra were subjected to a 99 point interpolation which produces an 
effective resolution of 0.01 nm.  
  
5.2.3  Far-UV Circular Dichroism   
Circular dichroism (CD) spectra were recorded from 190-260 nm with a 1 nm 
resolution at 20 °C.  Spectra were obtained with a Jasco J-720 spectrometer equipped 
with a Peltier controlled sample holder (Tokyo, Japan).  For thermal stress 
experiments, CD data were acquired at 222 nm from 10-85 °C at a rate of 15 °C/hr.  
This wavelength was chosen to monitor changes in the protein’s α-helical content.  
CD signals were converted to molar ellipticity using the Jasco software. 
   
5.2.4  Fluorescence Spectroscopy  
A PTI QM-1 spectrophotometer was used to collect fluorescence data.  For 
intrinsic Tyr fluorescence, the excitation wavelength was 275 nm and emission was 
recorded from 280-380 nm in 1 nm increments with a 0.5 s integration time.  In the 
case of ANS fluorescence, samples were excited at 372 nm with emission spectra 
acquired from 400-600 nm in 2 nm intervals.  ANS was added from a 2 mg/ml 
ethanol solution to CT584 to obtain a 10:1 molar ANS/protein ratio.  In both cases, 
emission was recorded by a photomultiplier tube (PMT) 90° from the angle of 
incident light.  Approximately 1 ml of the samples were pipetted into a 1 cm 
pathlength quartz cuvette and data were collected from 10-85 °C in 2.5 °C 
increments.  Light scattering was recorded simultaneously with the intrinsic 
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fluorescence acquisition with a second photomultiplier tube located 180° to the 
emission acquisition at 275 nm.  Blank solutions containing all of the chemical 
components except protein were also measured and the resultant spectra were 
subtracted from the protein emission spectra.  Peak positions were calculated in 
Origin® by fitting the data to a 2° polynomial curve followed by a first derivative 
calculation. 
 
5.2.5  Empirical Phase Diagrams   
Data from all the techniques described above were combined to create 
empirical phase diagrams (EPD).  The underlying theory and mathematics employed 
have been described in detail previously.37  In brief, data from the biophysical studies 
were formed into vectors with each vector representing a distinct pH/temperature 
setting.  A density matrix is formed by assembling these vectors which can be 
manipulated to calculate eigenvalues.  The three largest eigenvalues are selected and 
employed to create new eigenvectors which expand a truncated version of the data set 
in three dimensions.  Each dimension is assigned a color (red, green, and blue) and 
the data are expressed in an EPD by plotting these color assignments.  Thus, color 
assignments are arbitrary.  Not equilibria are implied across “apparent” phase 
boundaries and these are therefore not thermodynamic phase diagrams but are 




5.2.6  Fourier Transform Infrared Spectroscopy   
A Bruker (Billerica, MA) Tensor™ 27 FTIR spectrometer equipped with a 
ZnSe attenuated total reflectance (ATR) plate (Pike Technologies, Madison, WI) was 
used to collect Fourier transform infrared (FTIR) spectra at room temperature 25 °C.  
Data were collected over 256 composite scans with a resolution of 4 cm-1.  The 
samples were analyzed in 20 mM citrate/phosphate buffer at 1.8 mg/ml.  Water 
spectra were subtracted with the OPUS spectroscopy software associated with the 
spectrometer and data were further analyzed using GRAMS/AI software (Galactic, 
Inc.). The baseline was corrected between 1800 and 2400 cm-1 and the spectra were 
then smoothed using a 5 point Savitsky-Golay function.  Following Fourier self 
deconvolution, the Amide I/II bands of the spectrum (1500-1700 cm-1) were 
decomposed using a peaks fitting tool which employs Gaussian band profiles.  The 
second derivative spectra from 1500-1700 cm-1 provided the initial peak positions for 
fitting. 
   
5.2.7  Analytical Ultracentrifugation   
Protein molecular weight and oligomerization state were assessed using a 
Beckman Coulter XL-I analytical ultracentrifuge (Palo Alto, CA) in both 
sedimentation velocity and equilibrium modes.  For sedimentation velocity, CT584 
was diluted to 0.2 and 0.5 mg/ml in citrate phosphate buffer and injected into two 
channel, 12 mm optical path length cells.  A four-hole An60Ti rotor at 10 °C housed 
the cells and samples were run in triplicate at 36,000 rpm for 8 hrs.  Sedimentation 
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velocity analysis was conducted using SEDFIT (version 11.71) which was developed 
at the NIH by Peter Schuck.  Continuous c(s) distribution analysis was employed and 
both the Simplex and Marquardt-Levenberg models were tested to ensure the final fit 
was in a global minimum.  Both time and radial invariant noise were removed.  In 
equilibrium mode, the same settings were used as before except 6 channel 
centerpieces were included in the assembly and the rotor speed was 17,000 RPM with 
5 measurements taken hourly after a 12 hr delay.  Data were analyzed using 
SEDPHAT (version 6.21) with a monomer n-mer Self Association model giving the 
best fit both for global reduced Chi² and local RMSD values.   
 
5.3  Results 
5.3.1  Computational Structure Prediction and Homology Comparison 
Identifying candidate T3SS needle tip proteins using primary sequence 
homology has not proven useful in Chlamydia.  To identify potential T3SS needle tip 
candidates, computational structure prediction followed by a structural homology 
search was employed. I-TASSER is a hierarchal protein structure, molecular 
modeling program that incorporates a secondary-structure enhanced Profile-Profile 
Alignment and iterative implementation of the Threading Assembly Refinement 
program.39  This computational modeling program has proven to be the most effective 
program at accurately predicting protein 3D-structure blindly from primary 
sequence.40,41  Using this program, predicted structures of proteins with unknown 















Figure 5.1.  Protein Ribbon Structure of IpaD and I-TASSER Predicted 
Structure of C. trachomatis CT584. (A) IpaD from Shigella flexneri (PDB:2J0O) 
and (B) I-TASSER structural prediction of CT584. Region of shared structural 











function has previously been determined.  Similar to primary sequence homology 
BLAST analysis, this approach can provide candidates for subsequent functional 
analysis. 
One of the C. trachomatis proteins that exhibited predicted structural 
similarity to other T3SS needle tip proteins was ORF CT584.  The I-TASSER 
predicted structure of CT584 was compared pairwise (DaliLite) to each of the three 
determined T3SS needle tip protein structures known: IpaD (2J0O), BipD (2IXR), 
and LcrV (1R6F).42  This pairwise analysis will generate a Z-score indicative of the 
measure of quality for the alignment, with scores between 8-20 supporting an 
intermediate level of confidence that two proteins are homologous.  For reference, 
comparison of IpaD and BipD structures return a relatively high Z-score of 17.3 with 
220 amino acids aligned despite only 27% sequence identity.  In contrast, IpaD or 
BipD compared to LcrV results in a very low Z-score < 3.9, reflecting the structural 
differences between these functionally similar proteins.  Comparison of the predicted 
structure of CT584 to the structure of IpaD revealed an intermediate Z-score of 8.4.  
Only 108 amino acids of the predicted CT584 structure (of 184 total) were aligned to 
IpaD, although the aligned region is structured very similarly (Figure 5.1).  Given the 
structural homology between IpaD and BipD, it was expected that a pairwise 
comparison of CT584 with BipD should show some homology.  This analysis 
resulted in a Z-score of 6.9 and a region of structural similarity of 119 amino acids.  
In contrast to the results observed for IpaD and BipD, the Z-score for the LcrV 
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comparison to the predicted structure of CT584 was 2.1, close to a no confidence 
score (< 2.0). 
Overall, structural prediction of CT584 and comparison to known T3SS 
needle tip protein structures provided an intermediate level of confidence that CT584 
has structural similarity to T3SS needle proteins, specifically IpaD and BipD.  The 
predicted structure of CT584 forms two alpha-helical coil-coiled domains. While this 
is a widely distributed structural feature, needle tip proteins share this structure.29,43,44  
Size exclusion chromatography indicated that CT584 is forming a higher order 
complex (~150 kDa), possibly a hexamer or heptamer.  This molecular weight is very 
similar to that observed for natively purified T3SS needle tip proteins, including 
IpaD.29,45  To provide further support for the hypothesis that CT584 is a Chlamydia 
T3SS needle tip protein, biophysical characterization of this protein was performed 
and compared to prior studies that revealed protein sub-families based on their 
response to pH and temperature.34,35,46. 
 
5.3.2  Far-UV Circular Dichroism   
To characterize the secondary structure of CT584, circular dichroism (CD) 
and FTIR spectroscopy were employed  Both of these techniques permit quantitation 
of α-helical and β-sheet content in addition to turns and disordered structural 
elements.47,48  Circular dichroism spectra from 190 to 260 nm at 10 °C in pH 7 buffer 
indicate that, under physiologic conditions, the protein has primarily α-helical 
structure (Figure 5.2A).  This conclusion is based on the presence of two negative 
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peaks located at 208 and 222 nm.  Secondary structure analysis using the program 
Dichroweb estimates that the protein is 55% α-helical.  CD spectra were measured 
from pH 3 to 8 and the strongest minima were recorded at pH 3 suggesting that 
maximum secondary structure exists under more acidic condition.  In contrast, pH 6 
possessed the least α-helical content while pH 8 had minima nearly as strong as pH 3 
(not illustrated).   
 In addition to acquiring full length spectra at 10 °C, the intensity of the 
minimum at 222 nm was monitored as a function of temperature from 10 to 85 °C in 
2.5 °C increments (Figure 5.2B).  By thermally stressing the protein in this manner, 
the relative stability of the secondary structure can be ascertained.  CT584 shows only 
small changes in secondary structure at pH 3 and 6 compared to other conditions.  
Transitions from pH 4-8 show increasing transition onsets (T0) with T0 occurring near 
20 °C at pH 4 and at approximately 42 °C in the pH 8 environment.  The most 
distinctive trend is at pH 5 where there appears to be a biphasic transition initiating at 
27 °C.  This suggests the possible existence of at least two independently folding 
domains. 
   
5.3.3  FTIR 
Fourier transform infrared spectroscopy (FTIR) provides an orthogonal 
method with which to measure protein secondary structure and was performed here at 
pH 7 and 25 °C.  Estimation of secondary structural elements is possible by 


















































Figure 5.2.  Far-UV Circular Dichroism.  Spectra from 190 to 260 nm expressed in 
terms of molar ellipticity (A) and pH versus temperature trends at 222 nm monitored 
from 10 to 85 °C (B).  Error bars not shown.  , pH 3; , pH 4; ▲, pH 5; , pH 6; 























Wavenumber (cm-1)  
Figure 5.3.  Deconvoluted Amide I and II bands in solution measured by ATR-FTIR 
at 1.8 mg/ml and pH 7.  The Fourier self-deconvolution bandwidth and enhancement 
parameters were 21 and 2.5 respectively.  Six peaks were identified as secondary 









bands was accomplished using Fourier self-deconvolution with the second derivative 
trace of the spectra guiding initial peak position estimates.  From this analysis 6 peaks 
were clearly identified at 1695.5, 1683.7, 1674.2, 1652.9, 1635.9 and 1625.5 cm-1.  
The first two peaks are generally associated with β-turns, while peaks at 1674.7 cm-1 
and the two below 1650 cm-1 are attributed to β-sheet.48  The dominant peak, located 
at 1652.9 cm-1 and can be assigned to α-helical content. Based on the relative areas, 
helix comprises 60 % of the of the protein’s secondary structure which is within 5% 
of estimates from CD spectra.  β-sheet contribution to the Amide I peak is estimated 
to be approximately 30 % which compares with only 17% in CD analysis. 
  
5.3.4  Second Derivative UV Absorption Spectroscopy 
Tertiary structure can be monitored through a variety of spectroscopic 
techniques including intrinsic fluorescence, near-UV CD and second derivative UV 
absorption spectroscopy.  Intrinsic fluorescence is not useful here due to the 
insensitivity of Tyr residues to changes in environment.  Second derivative UV 
absorption spectroscopy provide a fairly global picture of tertiary structure changes 
since all three aromatic amino acid residues can be simultaneously monitored.49,50  
CT584 has 13 Phe, 1 Tyr and no Trp residues.  Representative second derivative 
negative peaks are shown in Figure 5.4 near 253, 259, and 265 nm.  These correspond 
to Phe and a final peak at 269 nm which arises from the lone Tyr residue.  The 
shallow slope seen at lower temperatures in all pH environments is not due to 
alterations in tertiary structure but rather to dynamic aspects of the proteins behavior 
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and suggests burial and immobilization of the Phe residues.  This phenomenon is 
discussed in detail elsewhere (in publication).  Initial peak positions are nearly 
identical under all pH conditions and are slightly longer (~0.5-1 nm) than observed in 
the free amino acid indicating that on average the aromatic residues are buried.37,49  
For the Phe negative peaks (Figure 5.4A-C), there is little change at pH 8 except in 
the peak centered at 265 nm where two or more transitions to longer wavelengths 
occur (the largest of which starts at 52 °C).  CT584 exhibits red shifts at pH 7 which 
manifest high error associated with aggregation.  Confirmation of this protein 
association is present in light scattering and turbidity data (Figure 5.5C-D).  At pH 5 
and 6, initial blue shifts lead to erratic data with large error which again is 
undoubtedly the result of protein aggregation.  The two most acidic pH environments 
examined for CT584 display less variation with temperature with the greatest changes 
occurring in the peak centered near 265 nm where a broad transition to longer 
wavelength takes place.  The Tyr peak centered around 269 nm again displays little 
discernable transition at pH 3 and 4 but distinct blue shifts accompanied by larger 
error are present at pH 5 and 6.  These shifts to shorter wavelength indicate a more 
solvent exposed state for the Tyr residue.  Aggregation, which coincides with this 
transition, again accounts for the increased variability.  Red shifts appear at pH 7 and 















































Figure 5.4.  Second derivative UV absorption spectroscopy.  Absorption peak 
position minima centered around 253 nm (Phe, A), 259 nm (Phe, B), 265 nm (Phe, C) 
and 269 nm (Tyr, D) are presented as a function of temperature from 10 to 85 °C.  
Error bars are the standard deviation from at least three trials.  , pH 3; , pH 4; ▲, 



































































































Figure 5.5.  IpaD ANS and light scattering studies.  ANS fluorescence wavelength 
peak position (A) and intensity (B) was monitored from 10 to 85 °C.  Light scattering 
intensities at 275 nm (C) and optical densities at 350 nm were measured under the 
same conditions.  Error bars are the standard deviation from at least three trials.  , 






  5.3.5  Extrinsic Fluorescence-ANS 
Extrinsic fluorescence using ANS as a probe was performed to monitor the 
appearance of apolar binding sites in CT584 with respect to both temperature and 
wavelength.  Initial peak positions are nearly identical at pH 4-6 but occur at shorter 
wavelengths under more acidic or basic conditions (Figure 5.5A).  Results at pH 7 
and 8 display low temperature red shifts which begin at ~15 °C and are followed by 
transitions to shorter wavelengths at midrange temperatures.  Trends in the middle 
range of pH (pH 4-6) manifest less pronounced blue shifts at lower temperatures.  
Peak position wavelength trends are less revealing at high temperatures where error, 
particularly at pH 5 and 6, precludes definitive conclusions.  In contrast, at pH 3 the 
general trend reveals a biphasic red shift suggesting the existence of two independent 
domains.   
Structural changes in CT584 can also be observed through examination of the 
fluorescence intensity of the ANS molecule.  ANS interacts strongly with apolar 
regions in proteins.  As the structure of a protein begins to loosen, the dye partitions 
into the apolar core causing an increase in its fluorescence quantum yield.51  Due to 
the negative charge of ANS in solution, there may also be some ionic interactions 
which might be expected more under acidic circumstances.52  Only broad, 
comparatively small transitions are observable below pH 5.  From pH 5-8, however, 
transitions occur at increasing temperature with respect to alkalinity (Figure 5.5B).  
T0 in the pH 8 environment, the most stable condition observed, begins at 
approximately 50 °C.  The initial fluorescence signal is highest at pH 5 indicating a 
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more disrupted three dimensional structure.  In contrast, the fluorescence intensity at 
pH 8 is nearly an order of magnitude lower than any other condition.  This lower 
quantum yield may be due in part to the pI of the protein (5.61) which would cause it 
to be more negatively charged in an alkaline environment.  Specifically, this pH is 
sufficiently far from the pKa of the 4 His residues and sufficiently close to the pKa of 
the 3 Cys to expect a significant alteration in charge state compared to even pH 7.  
Even with such a change in ionization state, however, it is likely that the tertiary 
structure at pH 8 is adequately compact to preclude the level of ANS binding 
observed in more acidic conditions.  
  
5.3.6  Aggregation 
In addition to secondary and tertiary structure changes, the stability of proteins 
can also be measured in terms of their aggregation behavior.  Light scattering 
provides insights into the formation of higher order aggregates and is more sensitive 
than turbidity measurements.  Alterations in static light scattering intensity may in 
some cases be the result of variation in the refractive index of scatterers.  Increases in 
scattering are, however, most often a consequence of a change in association 
behavior.  In this case, transition temperatures in light scattering data increase with 
respect to pH with the exception of pH 3 and 4 (Figure 5.5C).  At pH 3, the initial 
light scattering signal is less than half that observed under other conditions and 
remains lower than the decrease in intensity seen at ~ 40 °C at higher pH.  The initial 
decrease in intensity observed at pH 4-8 is probably due to changes in the 
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oligomerization behavior discussed in the analytical ultracentrifugation results section 
below (Figure 5.6).  Optical density data, recorded at 350 nm during the UV 
absorption experiments, also indicate increasing transition temperature occurring with 
higher pH (Figure 5.5D).  The exception again is environments below pH 5.  The OD 
transition onsets for all pH conditions begin at higher temperatures compared to the 
right angle light scattering results.  This phenomenon is attributed to the fact that light 
scattering is a more sensitive measure of aggregation. 
  
5.3.7  Analytical Ultracentrifugation 
 To gain a better understanding of the presence or absence of self-association 
events that may be occurring in CT584, the protein was analyzed using analytical 
ultracentrifugation (AUC) at 10 °C.  Some tip proteins are known to oligomerize in 
their native state and are reported to form pentamers or hexamers when localized to 
the needle tip.29,45,53,54  Samples of CT584 were examined in both sedimentation 
velocity and equilibrium modes using interference and absorption optical systems.  
Samples were run at 36,000 RPM at 0.5 and 1.0 mg/ml in velocity runs.  In Figure 
5.6A, the results from a continuous c(s) distribution analysis are shown at 0.5 mg/ml.  
The peak at 1.6 S corresponds to approximately 32 kDa, while the peak at 3.1 S is just 
over 88 kDa.  When the concentration was doubled to 1 mg/ml, the size of the first 
peak fell to 29 kDa while the sizes of the higher order species were also altered.  
Since the size of monomeric CT584 is just over 21.1 kDa and there is a change in the 
apparent size of species when concentration is varied, the oligomerization kinetics 
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must be fast on the time scale of sedimentation.55  Fast kinetics skews the apparent 
sizes of the species of interest in velocity analysis.  For this reason, CT584 was 
analyzed using sedimentation equilibrium as well.   
 Equilibrium runs were conducted at 0.5 mg/ml at 10 °C with a rotor speed of 
17,000 RPM.  The data were fit to multiple models.  Despite the complex self-
association phenomenon observed, the best fits occurred with the monomer-n-mer 
self-association model (Figure 5.6B).  A larger non-participating species set at the 
size of the smallest higher order aggregate (4.3 S) was included in this analysis to 
improve the fit.  The result shown in Figure 5.6B is monomer to pentamer with the 
residuals shown below.  The data were fit to four different equilibrium conditions and 
the global reduced Chi² was 1.4.  The pentameric and hexameric models both gave 
good fits.  Based the size of the second peak in the sedimentation velocity analysis, 
however, it is most likely that the correct model is monomer in equilibrium with 
pentamer with small amounts of higher order aggregation occurring. 
 
5.3.8  Empirical Phase Diagram 
  Empirical phase diagrams (EPDs) provide an effective way to summarize data 
from multiple techniques and enable one to get a more global picture of the effect of 
temperature and pH on protein structure.36-38,56  In addition, proteins with similar 
function but little sequence homology generally have similar EPDs which highlights 
the utility of this technique in considering structure/function relationships.38,46  In the 












































 Figure 5.6.  Analytical Ultracentrifugation.  Sedimentation velocity analysis for 
CT584 at 0.5 mg/ml and 36,000 RPM at 10°C using a continuous c(S) distribution 
model from SEDFIT (A).  Sedimentation equilibrium results 10 °C at 18,000 RPM 





































































Figure 5.7.  Empirical phase diagrams.  The empirical phase diagram is a way of 
summarizing data from different techniques and was created using all of the data 
biophysical techniques.  The empirical phase diagrams shown here are from IpaD 






differences from pH 6-8 (Figure 5.7C).  The difference between pH 7 and 8 is 
primarily due to ANS intensity data while pH 6 differs because of the CD results.  A 
small transition occurs at pH 7 near 15 °C which arises from a red shift in ANS 
wavelength peak position.  Ignoring this smaller transition, the trend of increasing 
stability with respect to pH above pH 4 is in agreement among the multiple 
techniques.  Acidic environments (pH 3 and 4) display more subtle changes in the 
empirical phase diagram. At pH 3, for example, the greater amount of secondary 
structure and the more buried aromatic residues seen in UV absorption data suggest 
that pH 3 may be more stable than any other condition.  The dramatic changes in 
color seen at high temperatures near the protein pI are generally indicative of 
aggregation and are in agreement with the parent data. 
 
5.4  Discussion 
 
 One reason for this biophysical characterization of CT584 is to explore the 
possibility that it functions as the tip protein in the T3SS of Chlamydia trachomatis.  
Tip proteins from other T3SSs have been thoroughly examined with biological 
assays,27,28,30,57-64 crystallographic methods,29,43,44 biophysical characterization and a 
number of other techniques.34,35,46  This work however, represents the first 
biophysical exploration of CT584 and one of the first studies of any kind of this 
protein.  As such, the data presented above should be compared to CT584 putative 
functional homologs.   
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 Previous work with EPDs has highlighted their utility in revealing 
structure/function relationships between proteins with minimal sequence 
homology.38,46  The tip proteins IpaD (Shigella flexneri), BipD (Burkholderia 
pseudomallei), SipD (Salmonella spp.), LcrV (Yersinia spp.) and PcrV (Pseudomonas 
aeruginosa) were compared in Chapter 2 and were shown to fall into two distinct sub-
families.46  The first sub-family (IpaD, BipD and SipD) produced EPDs that 
manifested different structures at pH 6 and 7 even at 10 °C (see example in Figure 
5.7A).  The physical states of the proteins were the same at pH 7 and above and, in 
general, were disrupted under acidic conditions below pH 5.  The second sub-family’s 
hallmark was nearly identical conformations at low temperatures from pH 5 to 8 with 
stability increasing in response to higher pH (see example in Figure 5.7B).  CT584’s 
phase diagram is similar to all of the tip proteins mentioned above in that there is a 
dramatic difference in protein structure (conformation) above and below pH 5.  This 
difference was associated with a disrupted physical structure in acidic media with the 
other T3SS proteins but may be a region of greater stability for CT584.  Defining 
which sub-family the Chlamydia protein most resembles is more challenging since it 
appears to posses one or more of the defining characteristics of each group.  Like the 
IpaD sub-family, CT584 displays conformational differences at low temperatures 
between pH 6 and 7 with the EPD color shift arising from changes in secondary 
structure.  The observed increasing stability as a function of rising pH, however, 
would place it in the LcrV subfamily.  It is tempting to speculate based on these two 
observations that, since Chlamydia trachomatis belongs to a different phylum than 
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the other bacteria mentioned, similarities to both sub-families trace it back to a 
common ancestor prior to the split in the protein family.   
 While EPD similarities to known tip proteins is not sufficient evidence to 
establish CT584’s function, the protein has other properties described here that 
strengthen the possibility.  Many of the T3SS tip proteins have been shown to 
oligomerize in vitro and in vivo and it is believed that, on the needle tip, they are 
pentamers or hexamers.29,45,53,54  AUC Sedimentation velocity and equilibrium 
analysis demonstrate that in aqueous solution, CT584 oligomerizes most probably to 
a pentamer with some higher order aggregates present.  If this self-association occurs 
in more biologically relevant situations, it suggests a similar role for the protein to 
other tip proteins.  Light scattering displayed an initial drop in intensity from 10 to 37 
°C at pH 7 and additional work is needed to ascertain if this change is due to an 
alteration in oligomerization properties or perhaps due to the formation of less dense 
particles. 
 Biphasic transitions are visible under various conditions as a function of 
temperature for CT584.  Circular dichroism traces at pH 5 and 6 as well as ANS peak 
position transitions in several environments display this behavior which suggests the 
presence of two independent folding domains.  This response to temperature is 
significant because IpaD and SipD have similar biphasic transitions and have been 
shown to possess N-terminal and C-terminal domains which have differences in 
thermal stability.34,35,46  
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Fourier transform infrared spectroscopy de-convolution results agree with the 
general conclusion from circular dichroism spectra that the secondary structure of 
CT584 is primarily α-helical.  FTIR secondary structural analysis, however, of most 
of the tip proteins from proteobacteria listed above revealed three predominate bands 
of nearly equal intensity which is indicative of coiled-coil structure.34,35,65,66  This 
structure has been confirmed by crystallographic studies of IpaD, BipD and 
LcrV.29,43,44  In the case of CT584, however, there is little evidence from 
spectroscopic data of a coiled-coil domain.  This does not, of course, completely 
preclude the possibility that some other intramolecular interaction is interfering with 
its detection.  For example, BipD’s trimeric coiled-coil alters its FTIR spectrum such 
that the bands are not longer equal in intensity.   
 This study provides the first detailed biophysical study of the putative 
Chlamydia trachomatis T3SS tip protein, CT584.  Secondary structural analysis 
reveals that the protein contains primarily α-helical structure, although not necessarily 
in the form of a coiled-coil.  The EPD of CT584 has characteristics in common with 
both sub-families of tip proteins previously subjected to this analysis.46  From pH 5 
through 8, the putative tip protein shows increased stability as a function of pH in 
most spectroscopic measurements.  Like other tip proteins, CT584 has complex 
oligomerization properties probably forming a pentamer with small amounts of higher 
order species also observed.  While much work remains, this study represents a first 
step in ascertaining the function of this newly discovered protein.  
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6.1  Overview 
 
 The bacterial pathogens discussed here are responsible for some of the most 
serious epidemics in the world.  Many gram-negative bacteria employ type III 
secretion systems (TTSS) to facilitate interactions with eukaryotic organisms as 
symbionts or pathogens.1,2  The TTSS apparatus is comprised of a basal body which 
spans the inner and outer bacterial membranes and a needle through which effector 
proteins translocate to subvert normal host cell functions.  A protein located at the 
needle tip regulates the secretion of other effectors.3,4  Due to its location and 
function, these so called tip proteins are excellent antigen candidates for sub-unit 
vaccines.   
 Previously, it was shown that these tip proteins possess a central coiled coil 
flanked by N and C-terminal domains.5-7  This structure appears to be dumbbell in 
shape.  The tip proteins discussed in Chapters 1 through 4 exhibit pI’s between 4.8 
and 5.5 with molecular weights between 33 and 37 kDa.  These proteins are predicted 
to oligomerize when interacting with the TTSS needle complex and possibly 
associate in other environments as well.7-9   
 Chapter 2 presents the biophysical characterization of the tip proteins IpaD 
from Shigella flexneri, BipD of Burkholderia pseudomallei, SipD of Salmonella spp., 
LcrV of Yersinia spp. and PcrV of Pseudomonas aeruginosa.  The conformational 
stability of these proteins was characterized as a function of pH and temperature.  
Secondary and tertiary structural changes were monitored using the spectroscopic 
techniques of far-UV circular dichroism, Trp fluorescence, ANS fluorescence and 
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ultraviolet absorption spectroscopy.  Optical density and right angle scattering 
measurements were also used to evaluate protein association/dissociation.  Finally 
data were combined and summarized using empirical phase diagrams (EPD).10,11 
 Responses of these tip proteins to pH and temperature reveal two distinct sub-
families.  The first is that of IpaD, BipD and SipD which reveal low temperature 
conformational differences at pH 5 and 6.  Many reasons may exist for these 
differences in conformation.  One interesting possibility is that the more acidic pH 
microenvironments present near host cell membranes may induce a functionally 
relevant conformational change in these proteins perhaps triggering the translocation 
of other effectors.12-14  The second sub-family includes LcrV and Pcrv and is 
characterized by increasing temperature transitions with higher pH.   
 Chapter 3 establishes the antigenicity of two of the TTSS tip proteins, IpaD 
and SipD.  Administration of these proteins adsorbed to aluminum salt adjuvant 
elicits a robust humoral immune response.  IpaD does not show significant dose-
dependent behavior when administered in a multi-dose regimen.  There appears, 
however, to be an initial dose-dependency following the first inoculation.  In the 
absence of Alhydrogel®, anti-IpaD IgG endpoint titers were reduced but still 
displayed values well above the titers of adjuvant alone.  The needle monomer MxiH 
antibody response was boosted when co-administered with IpaD.  The increased anti-
MxiH titers suggest that IpaD may possess some adjuvant like properties.  The SipD 
antibody response was also higher in the presence of the adjuvant.  The final endpoint 
titers of SipD antibodies were invariant relative to the amount of antigen injected.   
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 In Chapter 4, formulation experiments were conducted on the five tip proteins 
discussed in the second chapter.  After excipient screening and subsequent 
optimization experiments, 10% sucrose and 5% dextrose was selected as the optimal 
excipient combination.  Adsorption isotherms and desorption experiments were 
conducted to understand the nature of the interaction between the proteins and 
aluminum hydroxide adjuvant.  Based on these experiments, the interaction between 
the proteins and the adjuvant is probably a mixture of hydrogen bonding and Van der 
Waals forces although the relative importance of each varies by protein.  Excipients 
increased the transition midpoints of the tip proteins when adsorbed to Alhydrogel® 
in thermal stress studies conducted from 10 to 85 °C.  In long term stability 
experiments at 25 °C, intrinsic Trp fluorescence peak positions remained unchanged 
for a period of three months.  The excipient combination also inhibited chemical 
degradation at 40 °C compared to antigen adsorbed to aluminum hydroxide adjuvant 
alone.  The work in this chapter defines a formulation which, based on preliminary 
stability results, increases the stability of the tip proteins.  More long term 
experiments will be necessary to confirm this stabilizing capacity.   
 Chapter 5 presents the biophysical characterization of a putative tip protein 
(CT584) from Chamydiae.  Spectroscopic techniques were employed to measure 
conformational changes with respect to pH and temperature.  An EPD of CT584 
revealed possible structure/function characteristics in common with both sub-families 
explored in Chapter 2.10  In addition, analytical ultracentrifugation, in both velocity 
and sedimentation equilibrium modes, established that CT584 oligomerizes (most 
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likely to a pentamer).  Since other tip proteins are believed to pentamerize when 
associated with the needle complex, this suggests that CT584 may have a similar 
function.7,9,15,16 
 
6.2  Future Work 
   
 Animal studies and formulation experiments outlined in Chapters 3 and 4 
present evidence that a successful multivalent vaccine is possible.  More experiments, 
however, are necessary before such a vaccine becomes reality.  Animal challenge 
studies are needed to ascertain whether the tip proteins in the presence of 
immunopotentiators like aluminum hydroxide adjuvant protect for all the bacterial 
species against relevant challenges.  Specifically, no data exist on the protective 
effects of IpaD, BipD or SipD adsorbed to aluminum salt adjuvants in their individual 
systems.  Murine models exist for Yersinia pestis, some Salmonella enterica serovars, 
Burkholderia pseudomallei and Pseudomonas aeruginosa.17-20  Shigella flexneri, 
however, requires work in primates since the disease state currently can only be 
induced in that model.21   
 Additional long term stability studies need to confirm that the excipients 
identified increase both physical and chemical stability.  In particular, studies at 25 °C 
conducted for longer than three months (24-36 months) are necessary to ascertain the 
extent of conformational stability.  Ongoing studies at 4 °C also require additional 
measurements and analysis.  Chemical stability studies would be useful at lower 
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temperatures and longer times to confirm the results at 40 °C and to discover if 
chemical degradation pathways or their kinetics are altered under those conditions.  If 
alternative stability monitoring methods are required, standard ELISA protocols 
similar to those in Chapter 3 may yield useful information.  Additionally, effects of 
extended storage on potency should also be explored.  After shelf life has been 
estimated by conformational and chemical stability studies, administration of the 
vaccine formulation to animals is needed to confirm retention of potency.    
Another possible direction for future work involves synthesizing a sub-unit 
vaccine more analogous to the TTSS. This would be accomplished by combining the 
tip proteins discussed here with their polymerized needle counterparts.  Such a 
construct might elicit a more appropriate robust response and thus provide increased 
protection.  This approach requires additional work to better understand the nature of 
needle polymerization.  A method would need to be developed to manufacture 
recombinant needles with a defined, reproducible size distribution.  In addition, 
interactions between tip proteins and needles need increased analyses to ensure 
correct association of the two. 
 Finally, any future vaccine will ultimately require trials in humans.  Phase I 
trials would occur first to establish vaccine safety.  If successful, those studies would 
lead to Phase II and III trials.  As part of this process, testing in areas of the world 
where the diseases are endemic would provide valuable information on efficacy.  In 
view of the necessary future experiments, the work presented here represents only the 
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first few steps on a journey towards a multivalent, efficacious vaccine against these 
serious infections.  
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